A Study on factors influencing the outcome of thrombolysis in Acute Myocardial Infarction by Pratheesh, P P
A STUDY ON FACTORS INFLUENCING 
THE OUTCOME OF THROMBOLYSIS IN 
ACUTE MYOCARDIAL INFARCTION 
 
 
 
DISSERTATION SUBMITTED TO 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
for  
M.D. DEGREE IN GENERAL MEDICINE  
BRANCH -I 
 
 
 
CHENNAI 
APRIL 2011 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Certificate  
  
CERTIFICATE 
 
     This is to certify that this dissertation titled  "A STUDY ON  FACTORS 
INFLUENCING THE OUTCOME OF THROMBOLYSIS IN ACUTE 
MYOCARDIAL INFARCTION"  is submitted by DR.PRATHEESH.P.P  
to the TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY CHENNAI, 
in partial fulfillment of the requirement of the award of M.D. DEGREE 
BRANCH I ( GENERAL MEDICINE) is a original research work carried 
out by him under our direct supervision and guidance. 
 
 
PROF. DR. M. RAVEENDRAN, M.D., PROF. DR. S. VEERAKESARI, M.D., 
PROFESSOR AND UNIT CHIEF, PROFESSOR AND HEAD OF THE  
DEPARTMENT OF MEDICINE, DEPARTMENT,  
COIMBATORE MEDICAL COLLEGE,         DEPARTMENT OF MEDICINE, 
COIMBATORE. COIMBATORE MEDICAL COLLEGE, 
 COIMBATORE. 
 
Dr. R. VIMALA, M.D., 
THE DEAN 
COIMBATORE MEDICAL COLLEGE 
COIMBATORE 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Declaration 
  
DECLARATION 
 
 
  I solemnly declare that the dissertation titled “A STUDY ON 
FACTORS INFLUENCING THE OUTCOME OF THROMBOLYSIS 
IN ACUTE MYOCARDIAL INFARCTION” was done by me from 
March 2009 to October 2010 under the guidance and supervision of  
Professor Dr. M RAVEENDRAN.M.D. 
This dissertation is submitted to the TAMILNADU DR. M.G.R 
MEDICAL UNIVERSITY towards the partial fulfillment of the 
requirement for the award of M.D. DEGREE IN GENERAL MEDICINE 
(BRANCH I). 
 
         
 
Dr. PRATHEESH.P.P 
 
 
Place : Coimbatore     
Date  :  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgement  
  
ACKNOWLEDGEMENT 
  I express my thanks to our respected Dean DR. R. VIMALA M.D., our 
medical superintendent DR. A. MATHIVANAN, DCH. M.S, and former Dean 
DR. V. KUMARAN, M.S., MCH., for permitting me to conduct this study. 
I express my deep sense of gratitude to our Head of the Department, Prof. 
DR. S. VEERAKESARI.M.D, and former HOD Prof. DR. M.RAMASWAMY. 
M.D. for their valuable guidance. 
I owe a great debt of gratitude towards my Unit Chief  
Prof. DR. M. RAVEENDRAN, M.D., for his valuable suggestions and guidance 
to do this study. 
I extend thanks to Dr. NEDUMARAN, M.D., D.M., the Professor of 
therapeutics for his overwhelming enthusiasm and guidance during the entire 
duration of study. 
I whole heartedly thank my unit assistant professors,  
Dr.K.SWAMINATHAN, M.D., Dr. K. GANESAMOORTHY, M.D.,  
Dr. K. ARUL, M.D., for their able guidance. 
    I extent my gratitude to Head of Department of CADIOLOGY  
Prof. Dr.  D .DHARMARAJAN. M.D.,D.M., for his guidance and assistance 
during the entire study. 
I am indebted to all my Patients and their family members for their sincere 
cooperation, without whom this study would have not been successful. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents 
  
CONTENTS                                                             
 
 
TABLE OF CONTENTS   PAGE NO 
1. INTRODUCTION 1   
2. AIM OF THE STUDY 5  
3. REVIEW OF LITERATURE 6   
4. MATERIALS AND METHODS 53   
5. OBSERVATIONS AND RESULTS 57   
6. DISCUSSION 64   
7. CONCLUSION 71   
8. BIBLIOGRAPHY   
9. APPENDIX 
 ABBREVIATIONS  
 PROFORMA 
CONSENT FORM 
MASTER CHART   
    
                                  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
  
INTRODUCTION 
         Coronary heart disease (CHD) is a worldwide health epidemic. In the 
United States, for example, it is estimated that 13.7 million Americans have 
CHD, including more than 7.2 million individuals who already have had a 
myocardial infarction.1,2  From the 1960’s to the 1990’s the CAD prevalence  
increased two fold (from 2% to 4% )in rural India and three fold ( from 3.45 
to 9.45%) in Urban India. The prevalence is even higher in South India (13% 
urban and 7% rural). In 1990, 25% deaths in India were attributable to 
cardiovascular disease compared to diarrheal disease ,12% due to respiratory 
infections and 5% due to tuberculosis47. In the group of persons older than 
30 years of age, 213 per 100,000 individuals have CHD.1 Although age-
specific events related to CHD have fallen dramatically in the last few 
decades, the overall prevalence has risen as populations age and patients 
survive the initial coronary or cardiovascular event . Worldwide 30 percent 
of all deaths can be attributed to cardiovascular disease of which more than 
half are caused by CAD.  
Coronary Heart disease has been defined as impairment of heart 
function due to inadequate blood flow to heart compared to its needs caused 
by obstructive changes in the coronary circulation to the heart. 
It is the cause of 25- 30% of deaths in most of the industrialized 
countries. In India also it is a major public health problem. It is aptly called 
by WHO as the modern epidemic. The increasing incidence of coronary 
heart disease may a reflection of increased longevity, adoption of high fat 
diet based on meats decreased exercise made possible by increasing 
affluence.  It is not surprising to note that sir William Osler devoted only a 
few pages in his text book of  
Medicine published in 1892 to the discussion of Acute myocardial 
infarction. It was the brilliant work of Herrick in 1912 who performed 
autopsy on acute myocardial infarction patients that put forward the new 
concept of thrombotic occlusion of coronary artery as the cause of 
downstream necrosis of the heart muscle. Definite proof for the above said 
concept came from angiographic studies performed during the early hours of 
the acute event. This promoted scientists to systematically test the 
thrombolytic strategies to treat acute myocardial infarction. Scientists have 
developed many effective thrombolytic drugs like streptokinase, 
recombinant tissue plasminogen activator (Alteplase), Reteplase,  Urokinase, 
Tenecteplase etc. 
Evidence for the use of thrombolytic therapy came from large 
multicentric studies. GISSI and ISIS -2 confirmed reduction in mortality 
with the early use of streptokinase. ISAM (intravenous streptokinase in acute 
Myocardial Infarction study group) also stands as a proof of efficacy of 
thrombolytic drugs to reduce mortality. 
  Success rate of thrombolysis and thus the overall reduction in 
mortality is different among different agents used. The GUSTO-1 trial 
showed a 30 day mortality of 6.3 for accelerated t-PA verses 7.4% for 
streptokinase with intravenous heparin. In the GUSTO-1 trial in which 
alteplase was infused over 90 minutes there was a 14 % relative and a 1% 
absolute mortality reduction with alteplase compared with streptokinase at 
the cost of two extra strokes per 1000 patients randomized. In the GUSTO-
III Trial reteplase was the equivalent to alteplase but there was less major 
bleeding. Reteplase and Teneceplase being given only once. The bolus 
agents do not reduce mortality but certainly more convenient simpler to use 
and help to reduce medication errors. Of all the agents alteplase, tenecteplase 
and reteplase are licenced³ .  
But because of the prohibitive cost of t-PA, reteplase, and tenecteplase 
,streptokinase became the sheet anchor for the thrombolytic therapy in 
Coimbatore Medical College Hospital. Thrombolytic therapy has 
revolutionised  the management of acute myocardial infarction. GUSTO 
angiographic substudy showed a success rate of 54% at 90 minutes using 
streptokinase and Heparin.  
Thrombolytic therapy has been consistently proven to reduce the 
mortality and morbidity. Inspite of this it has been recognized that 
thrombolytic therapy has failed in significant population. There is lot of 
room for improvement. We need to identify the factors that are responsible 
for failure of thrombolysis. 
In this background we decided to look into our own patients who 
receive streptokinase for acute myocardial Infarction, in the coronary care 
unit of Coimbatore  Medical College Hospital. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim of the Study  
 
AIM OF THE STUDY  
1. To find out the overall success rate of thrombolysis in coronary care 
unit of Coimbatore medical college hospital. 
2. To find out whether the following parameters influence the outcome of 
thrombolysis. 
1. Age 
2. Sex 
3. Pre-infarction angina 
4. Alcohol intake 
5. Smoking status 
6. Pre existing systemic hypertension 
7. Diabetes mellitus 
8. Type of Myocardial Infarction. 
9. Time interval between the onset of pain and the initiation of                       
thrombolytic therapy. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
 
REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVE  
      The origin of myocardial infarction   - Already in ancient history it was 
noted that sudden pain in the chest could be a harbinger of death. The actual 
cause of death was not yet understood. First the circulation had to be 
described which was done by Harvey in the 17th century. Only at the 
beginning of the 20th century theories emerged on the Pathophysiology of 
myocardial infarction (MI), which was defined as necrosis of heart muscle 
tissue due to persisting ischemia. In 1910, Russian pathologists described 
five patients with acute MI of whom three showed coronary thrombosis at 
autopsy (Obraztsov,1910).  
           Subsequently, in 1912, Sir James Herrick wrote a publication on the 
syndrome of acute MI. He suggested that The clinical manifestations of 
coronary obstruction will evidently vary greatly depending on the size, 
location and number of vessels occluded. . Most of the observations hold 
good even after 90 years. So it was hypothesized for the first time that 
obstruction of the blood stream was the cause of subsequent necrosis and 
dysfunction of a part of the heart.4 The introduction of cardiac 
catheterization settled this dispute. Using this technique, a thrombus was 
shown in patients with symptoms and ECG signs of MI (DeWood,1980). 
This confirmed the view that acute thrombotic occlusion was the cause of 
MI. In addition, Falk and Davies showed that focal arterial lesions, in 
particular a fissured atherosclerotic plaque, were the origin of the thrombotic 
process (Falk,1983; Davies,1985). Adherence and aggregation of thrombi at 
the site of the culprit lesion preceded the development of fibrin 
(Davies,1979). Currently, the process of plaque rupture is more precisely 
understood (Richardson,1989; Chesebro,1991).5   
 PATHOLOGY 
Almost all MIs result from coronary atherosclerosis, generally with 
superimposed coronary thrombosis. Before the fibrinolytic era, clinicians 
typically divided patients with MI into those suffering a Q-wave and those 
suffering a non-Q-wave infarct on the basis of evolution of the pattern on the 
ECG over several days. The term Q-wave infarction was frequently 
considered to be virtually synonymous with transmural infarction, whereas 
non-Q-wave infarctions were often referred to as subendocardial infarctions. 
Contemporary studies using cardiac magnetic resonance imaging indicate 
that the development of a Q-wave on the ECG is determined more by the 
size of the infarct than the depth of mural involvement.6   
The hallmark of atherosclerotic coronary artery disease is the fibrous 
plaque.7 Plaque disruption exposes substances that promote platelet 
activation and aggregation, thrombin generation, and ultimately thrombus 
formation.8,9 The resultant thrombus interrupts blood flow and leads to an 
imbalance between oxygen supply and demand and, if this imbalance is 
severe and persistent, leads to myocardial necrosis. The atherosclerotic 
plaques of patients who died of STEMI are composed primarily of fibrous 
tissue of varying density and cellularity with superimposed thrombus. 
Calcium, lipid-laden foam cells, and extracellular lipid each constitute 5 to 
10 percent of the remaining area. A white thrombus is composed of platelets, 
fibrin, or both, and a red thrombus is composed of erythrocytes, fibrin, 
platelets, and leukocytes.   
 PLAQUE FISSURING AND DISRUPTION   
Atherosclerotic plaques considered prone to disruption over express 
metalloproteinase enzymes such as collagenase, gelatinase, and stromelysin 
that degrade components of the protective extracellular matrix.9 Activated 
macrophages and mast cells abundant at the site of atheromatous erosions 
and plaque disruption in patients who died of STEMI can elaborate these 
proteinases.10 A number of key physiological variables such as systolic blood 
pressure, heart rate, blood viscosity, endogenous tissue plasminogen 
activator(t-PA) activity, plasminogen activator inhibitor-1 (PAI-1) levels, 
plasma cortisol levels, and plasma epinephrine levels exhibit circadian and 
seasonal variations and increase at times of stress.   
 
ACUTE CORONARY SYNDROMES  
When plaque disruption occurs, a sufficient quantity of thrombogenic 
substances is exposed, and the coronary artery lumen may become 
obstructed by a combination of platelet aggregates, fibrin, and red blood 
cells that may produce an extensive thrombus filling a large segment of the 
infarct-related artery. An adequate collateral network that prevents necrosis 
from occurring can result in clinically silent episodes of coronary occlusion. 
Disruption of plaques is now considered to underlie most acute coronary 
syndromes (ACS)11 Characteristically, such completely occlusive thrombi 
lead to a large zone of necrosis involving the full or nearly full thickness of 
the ventricular wall in the myocardial bed subtended by the affected 
coronary artery and typically produce ST elevation on the ECG 2,3. Infarction 
alters the sequence of depolarization ultimately reflected as changes in the 
QRS.12 The most characteristic change in the QRS that develops in the 
majority of patients initially presenting with ST elevation is the evolution of 
Q waves in the leads overlying the infarct zone—leading to the term Q-wave 
infarction.13 In the minority of patients presenting with ST elevation, no Q 
waves develop, but other abnormalities of the QRS complex are frequently 
seen, such as diminution in R wave height and notching or splintering of the 
QRS. Patients presenting without ST elevation are initially diagnosed as 
suffering either from unstable angina or NSTEMI .The ACS spectrum 
concept, organized around a common pathophysiological substrate, furnishes 
a useful framework for developing therapeutic strategies.14ACS patients 
presenting without ST-segment elevation are not candidates for 
pharmacological reperfusion but should receive anti ischemic therapy, 
followed by PCI. All patients with ACS should receive antithrombin therapy 
and antiplatelet therapy regardless of the presence or absence of ST-segment 
elevation. Thus the 12-lead ECG remains at the center of the decision 
pathway for management of patients with ACS to distinguish between 
presentations with ST elevation and without ST elevation.15,14 
THROMBUS FORMATION  
Thrombus formation at the site of plaque disruption is the fundamental 
pathophysiological mechanism of unstable angina and acute myocardial 
infarction. 
ROLE OF PLATELETS  
This may be reviewed in three headings 
 Platelet adhesion  
 Activation with granular release  
 Platelet aggregation 
  
 Fig 1 -Necrosis begins in a small zone of the myocardium beneath the 
endocardial surface in the center of the ischemic zone. This entire region of 
myocardium (dashed outline) depends on the occluded vessel for perfusion 
and is the area at risk. A narrow zone of myocardium immediately beneath 
the endocardium is spared from necrosis because it can be oxygenated by 
diffusion from the ventricle.    
 FIG 2 : Acute coronary syndromes. The longitudinal section of an artery 
depicts the “timeline” of atherogenesis from (1) a normal artery, to (2) lesion 
initiation and accumulation of extracellular lipid in the intima, to (3) the 
evolution to the fibrofatty stage, to (4) lesion progression with procoagulant 
expression and weakening of the fibrous cap. An acute coronary syndrome 
develops when the vulnerable or high-risk plaque undergoes disruption of 
the fibrous cap (5); disruption of the plaque is the stimulus for 
thrombogenesis. Thrombus resorption may be followed by collagen 
accumulation and smooth muscle cell growth (6). Following disruption of a 
vulnerable or high-risk plaque, patients experience ischemic discomfort 
resulting from a reduction of flow through the affected epicardial coronary 
artery. The flow reduction may be caused by a completely occlusive 
thrombus (bottom half, right side) or subtotally occlusive thrombus 
(bottom half, left side).                                    
PLATELET ADHESION  
Platelets adhere to the subendothelial collagen immediately. 
Glycoprotein 1b on the platelet membrane links with the von willebrand 
factor (VWF) in the subendothelial collagen. The membrane receptor 
complex Glycoprotein II b/IIIa bind a number of relevant protein including 
VWF , fibrinogen and fibronectin. 
PLATELET ACTIVATION AND AGGREGATION 
Activated platelets release a number of substances like serotonin, 
ADP, PDGF(Platelet derived growth factor) ,Thrombospondin, VWF etc. 
PDGF plays a role in the proliferation and migration of smooth muscle cells 
after vessel damage .Released ADP binds to the specific receptors that 
change the conformation of Gp II b/IIIa complex so that it binds vWf, 
fibrinogen, fibrinonectin thus linking adjacent platelet into the haemostatic 
plug.16, 17, 18 
 SYSTEMIC FACTORS FAVOURING THROMBOGENESIS  
 1.Circulating catecholamines increases the platelet aggregability and 
thrombi formation. Smoking and emotional factors may be operating  by 
increasing the catecholamine levels in blood.  2. Elevated level of  
homocysteine  :-  This is toxic to endothelium and it decreases the capacity 
of endothelium to make nitric oxide and induces endothelium dysfunction. 
3.Diabetes mellitus :- Apart from accelerated atherosclerosis platelet activity 
and coagulation are increased in diabetics suggesting that it is a 
prothrombotic state.PAI –I  levels are also found to be higher in diabetics . 
4.Plasminogen Activator Inhibitor (PAI-I)  :- High levels are associated with 
increased risk of Acute coronary syndromes. 5. Elevated Apolipoprotein (a)  
may serve as a competitive inhibitor of plasminogen and cause a 
prothrombotic stage. 6. Elevated fibrinogen and Factor VII  :- It is another 
risk factor for thrombosis. Interestingly both are found to be elevated in 
advanced age, obesity, hyperlipidemia, diabetes, smoking and emotional 
stress. 19,21 
FIBRINOLYSIS 
Fibrinolysis starts at the same time of thrombogenesis  because 
elements of the fibrinolytic system are incorporated into the fibrin thrombus 
as it forms. 
COMPONENTS OF FIBRINOLYTIC SYSTEM  
1.PLASMINOGEN AND PLASMIN  
Plasminogen is a single chain glycoprotein sythesised primarily by 
liver. This is the precursor of the chief proteolytic enzyme plasmin. This 
conversion is facilitated by the binding of the plasminogen to fibrin 
(thrombus). Plasmin is capable of proteolyzing not only fibrin but also other 
proteins like fibrinogen ,coagulation factors V,VIII and extracellular matrix 
protein. 
2.PLASMINOGEN ACTIVATORS 
 Intrinsic activators of plasminogen are Kallikerin and Factor XIIa 
which are direct activators. Extrinsic activators are tissue type plasminogen 
activator (t-PA), High molecular weight two chain urokinase and Low 
molecular weight two chain Urokinase .EXOGENOUS ACTIVATORS :- 
These are used therapeutically in Acute Myocardial Infarction.Streptokinase 
, APSAC and staphylokinase belong to this category. 
TISSUE TYPE PLASMINOGEN ACTIVATOR 
(t-PA) is synthesized predominantely by vascular endothelial cells.It is 
a serine protease. In the absence of fibrin t-PA has little activity ,therefore t-
PA mediated activation of plasminogen in the plasma is minimal. Both 
single and two chain form of  t-PA have  proteolytic activity that is enhanced 
several hundred fold in the presence of fibrin . Free plasmin in the plasma is 
rapidly neutralized by cx2-plasmin inhibitor where as fibrin bound plasmin 
in protected from (x2 plasmin inhibitor).19,21,22 
UROKINASE TYPE PLASMIN ACTIVATORS  
Urokinase is aserine protease that is synthesized in the kidney as well 
as in endothelial cells and initially released as a single chain Urokinase (scu-
PA).  Limited proteolysis by plasmin converts scu-PA to high molecular 
weight two chain urokinase ( HMWtc UK). Like t-PA , HMW tc UK also 
has relative fibrin  selectivity but enhanced only 10 times by the presence of 
fibrin. 
ENDOGENOUS INHIBITOR OF FIBRINOLYSIS 
These inhibitors of plasminogen activators and plasmin belongs to 
serpin family. Thrombin induces PAI-I release from cultured human 
endothelial cells, so also endotoxin. During inflammatory states PAI –I 
levels are increased. There is diurnal variation in the circulating levels of 
PAI-I concentration which contribute to the clustering of Acute myocardial 
Infarction episodes during morning hours as well as resistance to 
thrombolytic  therapy. PAI-2 is found in the placental tissue where it plays a 
role in hemostasis. 
 REGULATION OF FIBRINOLYSIS 
Net activation of plasminogen is the result of a delicate balance among 
activators and inhibitors and protease receptor on the cell surface.Regulation 
and control of fibrinolysis occurs at several levels .Secretion of plasminogen 
activator inhibitor from endothelium,enhancement of plasminogen activation 
by fibrin and plasmin inhibition by alpha 2-antiplasmin inhibition .In 
addition certain cell types such as endothelial cells,monocytes and platelets 
have receptors for plasminogen activators which when occupied enhance 
plasminogen activation and localize plasmin activity to cell surface. By 
modulating the expression of these cell surface receptors cellular regulation 
of fibrinolysis is possible.20,21,22, 23 
ACUTE MYOCARDIAL INFARCTION 
SYMPTOMS 
Despite advances in the laboratory detection of STEMI, the patient's 
history remains crucial to establishing a diagnosis. The prodrome is usually 
characterized by chest discomfort, resembling classic angina pectoris, but it 
occurs at rest or with less activity than usual and can therefore be classified 
as unstable angina. A feeling of general malaise or frank exhaustion often 
accompanies other symptoms preceding STEMI.    
NATURE OF THE PAIN  
The pain of STEMI varies in intensity; in most patients, it is severe 
and in some instances intolerable. The pain is prolonged, usually lasting for 
more than 30 minutes and frequently for a number of hours. The discomfort 
is described as constricting, crushing, oppressing, or compressing; often the 
patient complains of a sensation of a heavy weight or a squeezing in the 
chest.   The pain is usually retrosternal in location, spreading frequently to 
both sides of the anterior chest, with predilection for the left side. Often the 
pain radiates down the ulnar aspect of the left arm, producing a tingling 
sensation in the left wrist, hand, and fingers.  . In some instances the pain of 
STEMI may begin in the epigastrium and simulate a variety of abdominal 
disorders, a fact that often causes STEMI to be misdiagnosed as 
“indigestion.”   In some patients, particularly the elderly, diabetic patients, 
and heart transplantation recipients, STEMI manifests clinically not by chest 
pain but rather by symptoms of acute left ventricular failure and chest 
tightness or by marked weakness or frank syncope. Diaphoresis, nausea, and 
vomiting may accompany these symptoms 
OTHER SYMPTOMS 
Nausea and vomiting may occur, presumably because of activation of 
the vagal reflex or stimulation of left ventricular receptors as part of the 
Bezold-Jarisch reflex. These symptoms occur more commonly in patients 
with inferior STEMI than in those with anterior STEMI. 24 
GENERAL APPEARANCE 
Patients suffering STEMI often appear anxious and in considerable 
distress. They often massage or clutch their chests and frequently describe 
their pain with a clenched fist held against the sternum (the Levine sign, 
named after Dr. Samuel A. Levine). Cough productive of frothy, pink, or 
blood-streaked sputum is common. Patients in cardiogenic shock often lie 
listlessly.   Depending on the degree of cerebral perfusion, the patient in 
shock may converse normally or may evidence confusion and disorientation.  
 HEART RATE  
The heart rate can vary from a marked bradycardia to a rapid regular 
or irregular tachycardia, depending on the underlying rhythm and the degree 
of left ventricular failure. Most commonly, the pulse is rapid and regular 
initially (sinus tachycardia at 100 to 110 beats/min), slowing as the patient's 
pain and anxiety are relieved; premature ventricular beats are common, 
occurring in more than 95 percent of patients evaluated within the first 4 
hours after the onset of symptoms. 
BLOOD PRESSURE  
The majority of patients with uncomplicated STEMI are 
normotensive, although the reduced stroke volume accompanying the 
tachycardia can cause declines in systolic and pulse pressures and elevation 
of diastolic pressure. Among previously normotensive patients, a 
hypertensive response is occasionally seen during the first few hours, with 
the arterial pressure exceeding 160/90 mm Hg, presumably as a consequence 
of adrenergic discharge secondary to pain, anxiety, and agitation.  Patients in 
cardiogenic shock by definition have systolic pressures below 90 mmHg and 
evidence of end-organ hypoperfusion. However, hypotension alone does not 
necessarily signify cardiogenic shock because some patients with inferior 
infarction with Bezold-Jarisch reflex activation may also transiently have 
systolic blood pressure below 90 mmHg.25 
CAROTID PULSE  
Palpation of the carotid arterial pulse provides a clue to the left 
ventricular stroke volume; a small pulse suggests a reduced stroke volume, 
whereas a sharp,brief upstroke is often observed in patients with mitral 
regurgitation or ruptured ventricular septum with a left-to-right shunt. 
Pulsus- alternans reflects severe left ventricular dysfunction. 
THE CHEST  
Moist rales are audible in patients who develop left ventricular failure 
and/or a reduction of left ventricular compliance with STEMI. Diffuse 
wheezing can present in patients with severe left ventricular failure. Cough 
with hemoptysis, suggesting pulmonary embolism with infarction, can also 
occur.  
In 1967 Killip proposed a prognostic classification scheme on the 
basis of the presence and severity of rales detected in patients presenting 
with STEMI.26 
Class I - patients are free of rales and a third heart sound.  
Class II- patients have rales but only to a mild to moderate degree 
(<50 percent of lung fields) and may or may not have an S3.  
Patients in class III have rales in more than half of each  lung field and 
frequently have pulmonary edema.  
   Class IV - patients are in cardiogenic shock. .26,17 
CARDIAC EXAMINATION  
Despite severe symptoms and extensive myocardial damage, the 
findings on examination of the heart may be quite unremarkable in patients 
with STEMI. 
PALPATION 
Palpation of the precordium may yield normal findings, but in patients 
with transmural STEMI, it more commonly reveals a presystolic pulsation, 
synchronous with an audible fourth heart sound, reflecting a vigorous left 
atrial contraction filling a ventricle with reduced compliance.   
AUSCULTATION    
HEART SOUNDS 
The heart sounds, particularly the first sound, are frequently muffled 
and occasionally inaudible immediately after the infarct, and their intensity 
increases during convalescence.Patients with marked ventricular dysfunction 
and/or left bundle branch block may have paradoxical splitting of the second 
heart sound. A fourth heart sound is almost universally present in patients in 
sinus rhythm with STEMI   A third heart sound in patients with STEMI 
usually reflects severe left ventricular dysfunction with elevated ventricular 
filling pressure.   
MURMURS  
Systolic murmurs, transient or persistent, are commonly audible in 
patients with STEMI and generally result from mitral regurgitation 
secondary to dysfunction of the mitral valve apparatus (papillary muscle 
dysfunction, left ventricular dilation). A new, prominent, apical holosystolic 
murmur, accompanied by a thrill, may represent rupture of a head of a 
papillary muscle. The findings in cases of rupture of the interventricular 
septum are similar, although the murmur and thrill are usually most 
prominent along the left sternal border and may be audible at the right 
sternal border as well. The systolic murmur of tricuspid regurgitation 
(caused by right ventricular failure because of pulmonaryhypertension and/or 
right ventricular infarction or by infarction of a right ventricular papillary 
muscle) is also heard along the left sternal border.   
FRICTION RUBS   
Pericardial friction rubs may be heard in patients with STEMI, 
especially those sustaining large transmural infarctions.28 Delayed onset of 
the rub and the associated discomfort of pericarditis (as late as 3 months 
postinfarction) are characteristic of the now rare post myocardial infarction 
(Dressler) syndrome. 
NEW DIAGNOSTIC CRITERIA FOR MYOCARDIAL INFARCTION 
Criteria for acute, evolving or recent MI :- Either one of the following 
criteria satisfies the diagnosis for an acute, evolving or recent MI: 
1) Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-
MB) of biochemical markers of myocardial necrosis with at least one of 
the following: 
a. ischemic symptoms; 
b. development of pathologic Q waves on the ECG; 
c. ECG changes indicative of ischemia (ST segment elevation or 
depression); or 
d. Coronary artery intervention (e.g., coronary angioplasty). 
2) Pathologic findings of an acute MI. 
Criteria for established MI:- Any one of the following criteria satisfies 
the diagnosis for established MI: 
1) Development of new pathologic Q waves on serial ECGs. The 
patient may or may not remember previous symptoms. 
Biochemical markers of myocardial necrosis may have normalized, 
depending on the length of time that has passed since the infarct 
developed. 
2) Pathologic findings of a healed or healing MI.29,30,31 
 ELECTROCARDIOGRAPHIC CRITERIA 
Electrocardiographic criteria for diagnosing acute myocardial 
infarction are the presence in the setting of chest pain of any one of the 
following, 
1. New or presumably new Q waves (atleast 30ms wide and 0.20mV deep) 
in at least two leads in any of the following groups (a)lead 
II,III,avF(b)Leads V1-V6 (6)leads I and avL. 
2. New or presumably new onset ST- elevation or depression >0.10mV 
measured 0.02 Sec after J point in two contiguous leads of the above 
mentioned lead combination. 
3. New or presumably new complete LBBB 
 ECG Showing inferior wall myocardial infarction 
 
 
 
ECG Showing anterior wall myocardial infarction 
  
ELECTROCARDIOGRAPHIC ESTIMATE OF INFARCT SIZE  
In general there is a direct relationship beween the number of leads 
showing st elevation and mortality.ST elevation in eight or nine lead is 
associated with a mortality of three to four times that of patients manifesting 
ST segment elevating in only two or three leads. 
DIAGNOSIS OF  RIGHT VENTRICULAR MI   
ST segment elevation in lead V4R is the single most powerful 
indicator of right ventricular involvement in inferior wall myocardial 
infarction. 
Localization of Ischemia or Infarction - The electrocardiographic leads 
are more helpful in localizing regions of transmural than subendocardial 
ischemia. As examples, ST elevation and/or hyperacute T waves are seen in 
the following: (1) one or more of the precordial leads (V1 through V6) and in 
leads I and aVL with acute transmural anterior or anterolateral wall 
ischemia; (2) leads V1 to V3 with anteroseptal or apical
32 ischemia; (3) leads 
V4 to V6 with apical or lateral ischemia; (4) leads II, III, and aVF with 
inferior wall ischemia; and (5) right-sided precordial leads with right 
ventricular ischemia. Posterior wall infarction, which induces ST elevation 
in leads placed over the back of the heart such as leads V7 to V9,
33 can be 
induced by lesions in the right coronary artery or left circumflex artery. 
These lesions can produce both inferior and posterolateral injury, 
which may be indirectly recognized by reciprocal ST depression in leads V1 
to V3. Similar ST changes can also be the primary electrocardiographic 
manifestation of anterior subendocardial ischemia. Posterior inferior wall 
infarction with reciprocal changes can be differentiated from primary 
anterior wall ischemia by the presence of ST segment elevations in posterior 
leads. The ECG can also provide more specific information about the 
location of the occlusion within the coronary system (the culprit lesion).34,35, 
36 ,37 require additional validation in test populations.   
S. 
No 
Categories Anatomy of Occlusion ECG Features 
1. Left main disease Left coronary artery 
ST ↑  in aVR, ST  ↓ in l,ll, v4 - 
v6  Sum of ST changes 18 
mm 
2. Proximal LAD 
Proximal to first septal 
perforator 
.ST↑in V1- V6 /  fascicular / 
budle branch block ST↑in 
V12.5mm 
.ST ↑in avR 
.Disappearance of preexisting 
Q waves in lateral leads 
3. 
Mid Left anterior 
descending 
Distal to first septal 
perforator, proximal to 
large diagonal 
ST↑ V1 –V6 , L1,  aVL 
4. 
Distal LAD or 
diagional 
Distal to large diagonal  
or diagonal it self 
ST ↑ V1 – V4 ,or ST↑ in 1, 
AVL,V5 ,V6 
 
5. 
Moderate  to large 
inferior 
Proximal  RCA or left 
circumflex 
ST ↑ ll,lll,avF,and any of the 
following V1,V3R,V4R V5 - 
V6 ,R > S in V1 , V2 
6. Small inferior 
Distal RCA or left 
circumflex branch 
occlusion 
ST ↑ ll,lll, avF only 
Enzymatic criteria for diagnosis of acute myocardial infarction 
1. Serial increase and then decrease of plasma CK-MB with change of 
>25 % between two values. 
2. CK-MB >10-13U/ L or >5% OF TOTAL CK activity. 
3. Increase in CK-MB activity >50% between any two samples separated 
by at least 4 hours. 
4. If only a single available CK-MB elevation > two fold. 
5. 5.Beyond 72 hours an elevation of Troponin T or Troponin I or LDH-
1>LDH-2  
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION 
Immediately begin continuous cardiac monitoring for patients with suspected 
ischemic type of chest pain and obtain intravenous access 
 
 
Treatment for the STEMI Patient 
1. Condition: continuous monitoring of cardiac status in ccu 
2. IV: NS on D5W to keep vein open. Start a second IV if IV 
medication is being given. This may be saline lock. 
3. Vital signs: every 1.5 hr until stable, then every 4 hr and as needed. 
Notify physician if HR is <60 beats/min or > 100 beats/min, BP is 
<100 mm Hg systolic or >150 mm Hg systolic, respiratory rate is < 
8 or > 22. 
4. Monitor: Continuous ECG monitoring for dysrhythmia and ST 
segment deviation 
5. Diet: NPO except for sips of water until stable. Then start 2 gm 
sodium/day, low saturated fat (<7% of total calories/day), low 
cholesterol (<200 mg/day) diet, such as total lifestyle change (TLC) 
diet 
6. Activity: Bedside commode and light activity when stable 
7. Oxygen: Continuous oximetry monitoring. Nasal cannula at 2 
liters/min when stable for 6 hr, reassess for oxygen need (i.e., O2 
saturation of <90%) and consider discontinuing oxygen. 
8. Medications:  
a. Nitroglycerin (NTG)  
1. Use sublingual NTG 0.4 mg every 5 min as needed for chest 
discomfort. 
2. Intravenous NTG for CHF, hypertension, or persistent ischemia. 
 
 
b. Aspirin (ASA; acetylsalicylic acid)  
1. If ASA not given in the emergency department (ED), chew 
nonenteric-coated ASA 162-325 mg. 
2. If ASA has been given, start daily maintenance of 75-162 mg 
daily; may use enteric coated for gastrointestinal protection. 
c. Beta blocker  
If not given in the ED, assess for contraindication (i.e., bradycardia 
and hypotension); continue daily assessment to ascertain eligibility 
for beta blocker.  
If given in the ED, continue daily dose and optimize as dictated by 
heart rate and blood pressure. 
d. Angiotensin-converting enzyme (ACE) inhibitor  
1. Start ACE inhibitor orally in patients with pulmonary 
congestion or LVEF <40 percent if the following are absent: 
hypotension (SBP <100 mm Hg or <30 mm Hg below baseline) 
or known contraindications to this class of medications. 
e. Angiotensin receptor blocker (ARB)  
1. Start ARB orally in patients who are intolerant of ACE 
inhibitors and with either clinical or radiological signs of heart 
failure or LVEF <40 percent. 
f. Pain medications  
IV morphine sulfate 2-4 mg with increments of 2-8 mg IV at 5- to 
15-min intervals as needed to control pain. 
g.  Anxiolytics (based on a nursing assessment) 
h. Daily stool softener 
  
GENERAL TREATMENT MEASURES 
ASPIRIN 
This agent is not only useful for the primary prevention of vascular 
events but is also effective across the entire spectrum of acute coronary 
syndromes and forms part of the initial management strategy for patients 
with suspected STEMI. The goal of aspirin treatment is to quickly block 
formation of thromboxane A2 in platelets by cyclooxygenase inhibition. 
Because low doses (40 to 80 mg) take several days to achieve full 
antiplatelet effect, at least 162 to 325 mg should be administered acutely in 
the emergency department.48 To achieve therapeutic blood levels rapidly, the 
patient should chew the tablet to promote buccal absorption rather than 
absorption through the gastric mucosa. 
CONTROL OF CARDIAC PAIN  
Analgesia is an important element of management of STEMI patients 
in the emergency department. Pain contributes to the heightened sympathetic 
activity that is particularly prominent during the early phase of STEMI. 
Control of cardiac pain is typically accomplished with a combination of 
nitrates, analgesics (e.g., morphine), oxygen, and beta-adrenoceptor receptor 
blockers .Morphine remains the drug of choice, except in patients with well-
documented morphine hypersensitivity. 4 to 8 mg should be administered 
intravenously, and doses of 2 to 8 mg repeated at intervals of 5 to 15 minutes 
until the pain is relieved or evident toxicity,hypotension, depression of 
respiration, or severe vomiting—precludes further administration of the 
drug. 
NITRATES  
By virtue of their ability to enhance coronary blood flow by coronary 
vasodilation and to decrease ventricular preload by increasing venous 
capacitance, sublingual nitrates are indicated for most patients with an acute 
coronary syndrome. At present, the only groups of patients with STEMI in 
whom sublingual nitroglycerin should not be given are those with inferior 
MI and suspected right ventricular infarction49 or marked hypotension 
(systolic pressure <90 mm Hg), especially if accompanied by bradycardia. 
Once it is ascertained that hypotension is not present, a sublingual 
nitroglycerin tablet should be administered and the patient observed for 
improvement in symptoms or change in hemodynamics. If an initial dose is 
well tolerated and appears to be of benefit, further nitrates should be 
administered, with monitoring of the vital signs.   
BETA BLOCKERS 
These drugs relieve pain, reduce the need for analgesics in many 
patients, and reduce infarct size and life-threatening arrhythmias. Avoiding 
early intravenous blockade in patients presenting in Killip Class II or greater 
is important, however, because of the risk of precipitating cardiogenic shock. 
50,51 A popular and relatively safe protocol for the use of a beta blocker in 
this situation is as follows. (1) Patients with heart failure (rales >10 cm up 
from diaphragm), hypotension (blood pressure <90 mm Hg), bradycardia 
(heart rate <60 beats/min), or heart block (PR interval >0.24 sec) are first 
excluded. (2) Metoprolol is given in three 5-mg intravenous boluses. (3) 
Patients are observed for 2 to 5 minutes after each bolus, and if the heart rate 
falls below 60 beats/min or systolic blood pressure falls below 100 mm Hg, 
no further drug is given. (4) If hemodynamic stability continues 15 minutes 
after the last intravenous dose, the patient is begun on oral Metoprolol, 50 
mg every 6 hours for 2 days, then switched to 100 mg twice daily. An 
infusion of an extremely short-acting beta blocker, Esmolol (50 to 250 
mg/kg/min), may be useful in patients with relative contraindications to beta 
blockade in whom heart rate slowing is considered highly desirable. 
OXYGEN  
Hypoxemia can occur in patients with STEMI and usually results  
from ventilation-perfusion abnormalities that are sequelae of left ventricular 
failure .Treating all patients hospitalized with STEMI with oxygen for at 
least 24 to 48 hours is common practice on the basis of the empirical 
assumption of hypoxia and evidence that increased oxygen in the inspired air 
may protect ischemic myocardium. However, this practice may not be cost-
effective.   oxygen should be administered to patients with STEMI when 
arterial hypoxemia is clinically evident or can be documented by 
measurement (e.g., SaO2 <90 percent).
48
 In these patients, serial arterial 
blood gas measurements can be employed to follow the efficacy of oxygen 
therapy. The delivery of 2 to 4 liters/min of 100 percent oxygen by mask or 
nasal prongs for 6 to 12 hours is satisfactory for most patients with mild 
hypoxemia.   
LIMITATION OF INFARCT SIZE    
In view of the prognostic importance of infarct size, the concept that 
modification of infarct size is possible has attracted a great deal of 
experimental and clinical attention.52,53 Efforts to limit the size of the infarct 
have been divided among several different (sometimes overlapping) 
approaches: (1) early reperfusion, (2) reduction of myocardial energy 
demands, (3) manipulation of sources of energy production in the 
myocardium, and (4) prevention of reperfusion injury. 
Assessment of Reperfusion Options for STEMI Patients 
Step 1: Assess time and risk. 
Time since onset of symptoms  ,Risk of STEMI , Risk of fibrinolysis  
,Time required for transport to a skilled PCI laboratory 
Step 2: Determine fibrinolysis or invasive strategy is preferred. 
If presentation is <3 hr and there is no delay to an invasive strateg y, 
there is no preference for either strategy. 
Fibrinolysis is generally preferred if: 
1. Early presentation (≤3 hr from symptom onset and delay to invasive 
strategy), 
2. Invasive strategy is not an option - Catheterization laboratory 
occupied or not available, Vascular access difficulties, Lack of access 
to a skilled PCI laboratory 
3. Delay to invasive strategy  - Prolonged transport , Door-to-Balloon)–
(Door-to-Needle) more than 1 hr, Medical contact-to-balloon or door-
to-balloon more than 90 min 
An invasive strategy is generally preferred if: 
1. Skilled PCI lab is available with surgical backup , 
2. Skilled PCI lab is available, defined by - Medical contact-to-balloon 
or door-to-balloon less than 90 min, Door-to-balloon)–(door-to-
needle) less than 1 hr , High risk from STEMI, Cardiogenic shock, 
Killip class ≥3, Contraindications to fibrinolysis including increased 
risk of bleeding and ICH, Late presentation, Symptom onset was more 
than 3 hr ago, Diagnosis of STEMI is in doubt 
 
HISTORY OF THROMOLYSIS 
Human blood has long been known to contain fibrinolytic activity. 
Well over 110 years ago Denys and Zimmerman observed that the fibrin of 
human blood obtained from wet cupping dissolved in 12 to 24 hrs. Dastre 
coined the term fibrinolysis. 
The property of spontaneous thrombolysis was used by Yudin of 
Russia who used blood from fresh copses (who were previously healthy, but 
died of accidents) for transfusion. 
          In 1933 Tillet and Garner at the John Hopkin’s medical school 
demonstrated that filtrates of both cultures of certain of hemolytic 
streptococcus contained a substances capable of inciting rapid fibrinolysis of 
human plasma clots.They named it streptococcal fibrinolysin. 
Christensen renamed it streptokinase in 1945.He demonstrated that SK 
activates an inactive precursor of a proteolytic enzyme,later found to be 
plasminogen. 
Streptokinase was clinically used first in 1947 by Tillet and Sol sherry 
in a young man who developed loculated bloody effusion in the left pleural 
cavity following pneumonectomy.The response was dramatic in that all the 
loculation were broken and a lysed coagulam was drained.  In 1977 FDA 
approved streptokinase and Urokinase for clinical use which opened the new 
clinical era of reperfusion therapy.54,55,56 
THROMBOLYTIC DRUGS 
NON FIBRIN SELECTIVE 
STREPTOKINASE:-Streptokinase is produced by beta-hemolytic 
streptococci. Streptokinase by itself is not a plasminogen activator, but it 
binds with free circulating plasminogen (or with plasmin) to form a complex 
that can convert additional plasminogen to plasmin. Streptokinase activity is 
not enhanced in the presence of fibrin.   Streptokinase is the least expensive 
fibrinolytic agent, but, unfortunately, it is antigenic and produces a high 
incidence of untoward reactions. This drawback limits the usefulness of 
streptokinase in the clinical setting. Although other fibrinolytic agents are 
more popular in developed nations like the United States, streptokinase 
continues to be widely used in developing nations. Studies with radioactive 
streptokinase indicate two disappearance rates: a "fast" half-life of 
approximately 18 minutes and a "slow" half-life of approximately 83 
minutes.57,58 Since it is produced from streptococcal bacteria, it often causes 
febrile reactions and other allergic problems. It can also cause hypotension 
that appears to be dose related. Streptokinase usually cannot be administered 
safely a second time within 6 months, because it is highly antigenic and 
results in high levels of antistreptococcal antibodies.57,58,59 
Adverse effects :- Hypotension is the most common adverse effect which 
ranges from 10 – 40 % of SK administration.Allergic reactions reported 
included fever ,chills,urticaria,rash,flushing and muscle pain.Minor bleeding 
can occur especially from vascular puncture and access site.Manual 
compression for 30 mts or until bleeding stops is usually 
effective.Intracranial bleeding is the dreaded complication. Total stoke 
incidence in GISSI/international trial was 0.9%,in ISIS 3 trial it was 1%.57,58 
MODE OF ADMINISTRATION   
1.5million units of SK administrated over 1 hour is the standard 
regimen.More rapid administration can lead to hypotension and should be 
avoided. 
Urokinase 2 
Urokinase (Abbokinase, Kinlytic) 58 ,60  is the fibrinolytic agent most 
familiar to interventional radiologists and the one that has been used most 
often for peripheral intravascular thrombus and occluded catheters.        
Urokinase is a physiologic thrombolytic agent that is produced in renal 
parenchymal cells. Unlike streptokinase, urokinase directly cleaves 
plasminogen to produce plasmin.   Allergic reactions are rare, and the agent 
can be administered repeatedly without antigenic problems 
RELATIVELY FIBRIN SPECIFIC AGENTS : TISSUE TYPE 
PLASMINOGEN ACTIVATOR  (t-PA) 
Alteplase (tPA, Activase) was the first recombinant tissue-type 
plasminogen activator and is identical to native tissue plasminogen activator.   
It is the physiologic thrombolytic agent responsible for most of the body's 
natural efforts to prevent excessive thrombus propagation. Alteplase is fibrin 
specific with a plasma half-life of 4-6 minutes. It is the fibrinolytic agent 
most familiar to emergency departments.40,41 Alteplase may be re-
administered as necessary, as it is not antigenic and almost never is 
associated with any allergic manifestations. The accelerated infusion of 
alteplase (tPA) for acute MI is 15 mg IV bolus, followed by 0.75 mg/kg (up 
to 50 mg) IV over 30 minutes, then 0.5 mg/kg (up to 35 mg) IV over 60 
minutes. The maximum total dose is 100 mg for patients weighing >67 kg. 
This is the most common alteplase infusion parameter used for acute 
myocardial infarction. 
Reteplase  
(r-PA, Retavase) is a second-generation recombinant tissue-type 
plasminogen activator that seems to work more rapidly and to have a lower 
bleeding risk than the first-generation agent alteplase.   
 
Tenecteplase (TNKase)  
TNKase was approved by the FDA as a fibrinolytic agent in 2000. 
This drug has a similar mechanism of action as alteplase (tPA). It is the latest 
thrombolytic agent approved for use in clinical practice. TNKase is currently 
indicated for the management of acute myocardial infarction (AMI). 42 
TNKase has the advantage for a single bolus administration and decreased 
bleedingside effects due to high fibrin specificity. The ASSENT-2 trial 
evaluated the efficacy and safety of tenecteplase compared with alteplase in 
patients with AMI. Tenecteplase was found noninferior to alteplase in terms 
of 30-day mortality.43 Follow-up study showed that mortality rates between 
the two active therapy groups remained similar after one year.44 
PATENCY OF INFARCT RELATED ARTERY 
Angiographic assessment :- TIMI grading is used to assess the angiographic 
patency 
Grade of flow Definition 
0 Complete occlusion 
1 Penetration without perfusion.Coronary bed distal to occlusion 
fails to opacify completely. 
2 Partial perfusion .Full but slow opacification of coronary bed 
distal to occlusion. 
3 Complete perfusion 
CLINICAL DETECTION OF REPERFUSION   
Sudden disappearance of chest pain is associated with successful 
thrombolysis.But this is difficult to assess in the CCU setup when most of 
the patients receive opioid analgesics.  
ECG : A BETTER PREDICTOR OF PERFUSION AT MICROVASCULAR 
LEVEL 
Recent studies have suggested that achievement of TIMI grade flow in 
infarct related artery is not itself indicative of successful myocardial 
reperfusin.61,62 Myocardial contrast echocardiography has shown that even in 
the presence of normal epicedial flow after PTCA impaired myocardial 
perfusion at tissue level can occur and is associated with poor recovery of 
LV function. Resolution of ST-segment elevation on the surface ECG 
correlates closely with findings at contrast echocardiography.63 Less than 5 
0% resolution of ST- segment elevation in the worst lead and no accelerated 
idioventricular rhythm has sensitivity of 81 %, specificity of 88% positive 
predictive value of 87%,negative predictive value of 83% and overall 
accuracy of 85% in prdecting < TIMI 3 flow in infact related vessels. 64 
PROGNOSTIC SIGNIFICANCE OF ST RESOLUTION 
James A de lemos et al. reported that 30 days mortality was 2.4% 
among patients who attain >70% ST resolution at 90 minutes where as it was  
8.1% in those with <30% ST resolution. 65  
FACTORS INLUENZING THE SUCCESS OF THROMOLYSIS 
1. TIME INTRAVAL BETWEEN PAIN ONSET AND TO 
INITIATION OF THROMBOLYTIC THERAPY : Thus is the 
most  important variable affecting the success of thrombolysis. As the 
window boardens not only more and more myocardium gets necrosed 
but also thrombus gets organized and become more resistant to lysis. 
2.  STRUCTURE OF THROMBI : Thrombi rich in platelets are more 
resistant to lysis than fibrin rich thrombi. 
3. CIRCARDIAN RHYTHM : A morning resistence to thrombolytic 
therapy was observed by Braunwald et al . Where as better success 
rate of thrombolysis was found by E Gold Hammer et al. When SK 
was administterd between 4:00pm – 8:00pm hours. 
4. PREINFARCTION ANGINA : Patients with acute myocardial 
infarction who have intermittent infarct related pain or unstable angina 
in the seven days preceding the infarction have faster coronary artery 
perfusion and smaller infarsts after thrombolytic therapy than patients 
without preinfarction angina. (24) this may be an additional 
mechanism for the better prognosis in these patients ,the other 
proposed mechanism being ischemic preconditioning. 
5. SEX : Eventhough mortality is high among woman who develop 
acute myocardial infarction,compared to men ,the rate of induction of 
coronary patency with thrombolytic drugs are coparable in 
woman.Mensturation is not a contraindication for thrombolytic 
therapy because menstrual bleeding is related more to sloughing of 
tissue than active bleeding. 
6. CONGESTIVE HEART FAILURE AND CARDIOGENIC 
SHOCK : No significant reduction in mortality occurs when the killip 
class IV patients are treated with SK. This may be due to low rate of 
adequate recanalisation. 
7. ELDERLY PATIENT : Risk of hemorrhagic complications are high 
in those aged above 75 years. 
8. REPERFUSION INJURY : The process of reperfusion, although 
beneficial in terms of myocardial salvage, may come at a cost because 
of a process known as reperfusion injury. Several types of reperfusion 
injury have been observed in experimental animals. These consist of 
(1) lethal reperfusion injury—a term referring to reperfusion-induced 
death of cells that were still viable at the time of restoration of 
coronary blood flow; (2) vascular reperfusion injury—progressive 
damage to the microvasculature such that there is an expanding area 
of no reflow and loss of coronary vasodilatory reserve; (3) stunned 
myocardium—salvaged myocytes display a prolonged period of 
contractile dysfunction following restoration of blood flow because of 
abnormalities of intracellular metabolism leading to reduced energy 
production; and (4) reperfusion arrhythmias—bursts of ventricular 
tachycardia and on occasion ventricular fibrillation that occur within 
seconds of reperfusion.66,67 The available evidence suggests that 
vascular reperfusion injury, stunning, and reperfusion arrhythmias can 
all occur in patients with STEMI. 
REPERFUSION ARRHYTHMIAS   
Transient sinus bradycardia occurs in many patients with inferior infarcts at 
the time of acute reperfusion; it is most often accompanied by some degree 
of hypotension. This combination of hypotension and bradycardia with a 
sudden increase in coronary flow has been ascribed to the activation of the 
Bezold-Jarisch reflex.48,68,69 Premature ventricular contractions, accelerated 
idioventricular rhythm, and nonsustained ventricular tachycardia are also 
seen commonly following successful reperfusion.   
CATHETER-BASED REPERFUSION STRATEGIES  
Reperfusion of the infarct artery can also be achieved by a catheter-
based strategy. This approach has evolved from passage of a balloon catheter 
over a guidewire to now include potent antiplatelet therapy (intravenous 
glycoprotein [GP] IIb/IIIa inhibitors, thienopyridines) and coronary stents.48 
When PCI is used in lieu of fibrinolytic therapy, it is referred to as direct or 
primary PCI. When fibrinolysis has failed to reperfuse the infarct vessel or a 
severe stenosis is present in the infarct vessel, a rescue PCI can be 
performed. A more conservative approach of elective PCI can be used to 
manage STEMI patients only when spontaneous or exercise-provoked 
ischemia occurs, whether or not they have received a previous course of 
fibrinolytic therapy. 
SURGICAL REPERFUSION 
 Despite the extensive improvement in  intraoperative preservation 
with cardioplegia and hypothermia and numerous surgical techniques it is 
not logistically possible to provide surgical reperfusion in a timely fashion. 
Therefore patients with STEMI who are candidates for reperfusion routinely 
receive either fibrinolysis or PCI. However, about 10 to 20 percent of 
STEMI patients are currently referred for coronary artery bypass grafting 
(CABG) for one of the following indications: persistent or recurrent chest 
pain despite fibrinolysis or PCI, high-risk coronary anatomy (e.g., left main 
stenosis) discovered at catheterization, or a complication of STEMI such as 
ventricular septal rupture or severe mitral regurgitation caused by papillary 
muscle dysfunction.70,71 
 
RECURRENT CHEST PAIN 
The most common cause of recrrent chest pain after AMI are coronary 
ischemia and pericarditis. 
POSTINFARCTION ANGINA  
Postinfarction angina is caused by recurring or worsening ischaemia 
after the initial acute necrosis.it is defined as chest pain that is frequently 
similar to the original discofort occurring at rest or with limited activity 
during hospitalization 24 hours or more after onset of the of AMI.This pain 
may or may not be associated with ST segment elevation or depression or 
with pseudonomalisation of inverted T waves on post n=myocardial 
ischaemia ECG. The incidence of AMI angina is almost twice as high after 
non Q myocardial infarction than Q wave myocardial 
infarction.Thrombolytic therapy also lead to a high incidence of post 
infarction angina,with a 12 – 15% incidence of reinfarction during te early 
experience with lytic therapy for reperfusion. 
APPROACH TO POST INFARCTION ANGINA 
If there is persistent pain lasing >30 minutes a reelevation of CK-MB 
and ST –T changes consider readministration of thrombolytic therapy (rt-
PA).The other option is immediate coronary angiography and PTCA. 
 COMPLICATIONS OF ACUTE MYOCARDIAL INFARCTION 
DYSARRHYTHMIAS  
Bradycardia - Relatively common (30-40%)  early in the course of 
acute myocardial infarction especially in inferior infarction or  after 
reperfusion of right coronary artery because of activation of vagal afferents 
that ultimately result in enhanced parasympathetic tone .Atrpine in doses of 
0.5 – 1mg is the drug of dose if hypotension tissue hypoperfusion coexists.72 
AV BLOCK,VENTRICULAR ASYSTOLE   
Atropine is useful for treatment of type 1 second degree AV block 
especially if complicating inferior wall MI and at times in third degree AV 
block of AV node in restoring  AV conduction or for increasing functional 
response rate .For ventricular asystole atropine is used in doses of 1.0mg 
every 3-5 minutes during CPR upto a maximum of 2.5 mg if asystole 
persists.73,74,48 
HEART BLOCK 
A heart block in the stting Anterior MI reflects extensive infarction 
and concomitant destruction of the conducting system and is associated 
relatively high mortality. In contrast heart block with inferior myocardial 
infarction may primarily reflect ischemia of AV node rather than extensive 
tissue damage and so is associated with a better prognosis.48,73 
VENTRICULAR FIBRILLATION  
Ventricular fibrillation can occur in 3-5% acute myocardial infarction 
patients in the initial 4 hours. It is called primary VF. The mechanism is 
thought to be micro reentry in the infarct zone. Triggering factors include 
hypokalemia, hypomagnesemia, enhanced adrenergic tone ,acidosis, 
Increased intracellular calcium, increased free fatty acids and reperfusion 
induced production of free radicals.  Incidence of VF is decreased by the use 
of beta blockers .Prompt defibrillation using unsynchronized shock starting 
with 200j is the treatment of choice.If unsuccessful give another shock 
immediately with 200-300 J.If again persists shock with energy level of 
360J.48,73 
VENTRICULAR TACHYCARDIA 
Polymorphic VT causing hemodynamic collapse is treated with 
unsynchronized shock starting with 200 J. monomorphic VT with 
hypotension pulmonary edema or angina should be treated with a 
synchronized shock with an energy level starting at 100 J initially. 
Hemodynamically stable ventricular tachycardia is treated with intravenous 
lidocaine 1-1.5 mg/kg IV bolus with supplemental doses of 0.5 -0.75 mg /kg 
every 5 -10 minutes upto a maximum of 3 mg /kg if needed.This is followed 
by an onfusion of 2 – 4mg /min  for 24 hours . Other dysrrhythmia that can 
occur during Acute myocardial infarction are ventricular ectopics,atrial 
flutter and fibrillation, functional rhythm.48,75,76 
ACCELERATED IDIOVENTRICULAR RHYTHM  
Normally occur frequently during the first hours of acute myocardial 
infarction and occur after thrombolysis as a perfusion arrhythmia. 
Accelerated idioventricular rhythm should not be treated .When the rate 
exeed 120 mg /mt it should not be treated. When the rate exeed 120/mt it 
should be considered as an autonomic rhythm for which suppression with 
lidocaine should be considered.48,75,76 
MECHANICAL COMPLICATIONS  
Mechanical complications are cardiogenic shock papillary muscle 
dysfunction ,papillary muscle rupture ,ventricular septal rupture,cardiac 
rupture ,ventricular aneurysm formation and pseudoaneurysm. 
CARDIOGENIC SHOCK   
Cardiogenic shock may occur when 40% or more of left ventricle is 
infracted .It is the most common cause of   in hospital death in acute 
myocardial infarctionpatients .mortality rate is around 80%.The  incidence of 
cardiogenic shock has decreased from 15% in the early 1970s to 
approximately 5-7% . This is attributed to use of thrombolytic therpy and 
better treatment of angina and ischemia. 
Characteristics of cardiogenic shock are 1) Evidence of hypoperfusion 
: Cold. clammy skin, impaired mentation, oliguria. 2) Systolic blood pressure 
< 80-90mm Hg. 3) Left ventricular end diastolic pressure or pulmonary 
capillary wedge pressure    18 mmHg. 4) Evidence of primary cardiac 
abnormality. 4) Cardiac index 1.8/mt/m. 
MANAGEMENT OF CARDIOGENIC SHOCK  
MAINTENANCE OF TISSUE PERFUSION 
  When systolic BP is more than 90 mm Hg intravenous dobutamine 
infusion is tried .When systolic pressure is below 70 – 90 mm Hg dopamine 
is the preferred agent so to bring the blood pressure to 90 – 100 mm Hg .If 
high doses of dopamine are necessary to maintaine adequate perfusion 
,norepinephrine may be substituted for dopamine because norepinephrine 
has more alpha agonist effect and lesser chronotropic and ionotropic action 
of betareceptor stimulation.  Early mechanical revascularization by PTCA  
or CABG improves survival .In the waiting period intra aortic balloon 
counter pulsation may be used to buy time .Thrombolytic therapy should be 
administered if facilities for percutaneous intervention procedures are 
available. 
PAPILLARY MUSCLE RUPTURE  
It occur in 1%  of MI.Posteromedial papillary muscle is involved 6 – 
12 times than that of anterolateral .Rupture occurs more often distally 
involving one or several of small heads of muscle .Usually manifests 2-7 
days after infarction with the development of pulmonary edema.Mural valve 
replacement or repair is the treatment of choice. 
PAPILLARY MUSCLE DYSFUNCTION  
More common than rupture. Again poseromedial muscle is more often 
involved.Dysfunction may be transient during ischemia which can disappear 
with successful treatment. 
VENTRICULAR SEPTAL RUPTURE  
Incidence is 1-35 of acute myocardial infarction equally divided 
among anterior and inferior infarctio. It occur more often in first infarction 
and in the first week. Usually manifest by appearance of new 
harsh,holosystlic mrmur along the left sterna border and sudden clinical 
deterioration with hypotension and pulmonary congestion. Management is  
essentially surgical closure. 
CARDIAC RUPTURE : 
Free wall of the ventricle is the most common site of rupture . 
Generally occure within the first 2 weeks and may occur   within 24 hours.It 
occure more often in the first infarction, woman , elderly, and with systemic 
hypertension particularly if there is no associated left ventricular 
hypertrophy. It generally presents as sudden unanticipated death. 
Other complications that may occur are pulmonary thromboembolism 
and systemic embolism.77,78,79 
CONTINUING MANAGEMENT  
Uncomplicated AMI patients can be transferred from CCU by 3rd day. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
  
MATERIALS AND METHODS 
PLACE OF STUDY 
This study was conducted in the coronary care unit of Coimbatore 
medical college hospital, Coimbatore 
PERIOD OF STUDY 
From  MARCH 2009 – OCTOBER 2010 
DESIGN  
Observational prospective cohort study of patients receiving 
streptokinase for acute myocardial infarction. A total of 83 patients were 
included in the study. 
METHODOLOGY   
Subject selection 
1. Inclusion criteria 
a)  Presence of typical chest pain suggestive of Acute myocardial 
infarction along with ECG evidence of acute myocardial infarction. 
Criteria for thrombolysis being 2mm or more ST elevation in two 
contiguous limb leads.  
b) Time window of 12 hrs from the onset of pain to the initiation of 
thrombolysis. 
2.  Exclusion criteria 
a) Late thrombolysis (more than 12 hrs from the onset of  pain).  
b) Recurrent myocardial infarction.         
c) Presence of bundle branch block. 
d) Development of pericarditis. 
DRUG THERAPY  
- All patients received streptokinase 1.5 million units im 100 ml of 
normal saline over 60 minutes.  
- Aspirin was given to all patients 
- Use of hepain,  Beta blockers , ACE inhibitors was according to CCU 
protocols which was in the accordance with ACC/AHA 
recommendations. 
CRITERIA FOR SUCCESS OF THROMBOLYSIS 
Success was defined by  
1.  Clinical  complete subsidence of chest pain 
2. Electrocardiographyically more than 50% ST resolution in a lead 
which showed maximum ST elevation initially. ST elevation is 
measured manually 80 ms after J point from isoelectric line . 
Patients were analyzed for success of thrombolytic therapy at 90 
minutes after initiation of thrombolytic therapy , applying the above 
mentioned criteria. Those who underwent successful thrombolysis were 
grouped into group A. 
Those with failed thrombolysis grouped into group B 
  The following parameters were analyzed among them to know 
whether they influenced the outcome of thrombolysis. 
(1)  Age   (2) Sex  (3) Time of SK administration (4) Preinfarction 
angina (5) Alcohol intake (6) smoking status (7) Systemic hypertension (8) 
Diabetes mellitus (9) Location of MI  (10) Time interval between the onset 
of pain and the initiation of thrombolytic  therapy. 
DEFINITIONS  
Smoking : Patients are considered smokers if they were using tobacco for 
smoking in any form currently. Ex-smokers were defined as those who 
quitted smoking for more than 1 tear back from the date of admission. 
Diabetes mellitus :- Patients were considered to be diabetic when  
1. Currently on oral hypoglycemic drugs and /or insulin or  
2. Fasting plasma glucose > 126 mg% or 2 hr post prandial plasma 
glucose >200mg% on more than 2 occasions. 
Hypertension  :- Patients were considered hypertensive when  
1. They are already on the antihypertensive drugs 
2. Medically documented Blood pressure elevation more than 140/90 
mmHg, on two occasions in the past. 
Preinfarction angina : It was defined as history of angina pain during the 
preceding 7 days of the acute  event causing hospital admission. 
Location of myocardial infarction : Inferior wall infarction :- In Patients 
with ST elevation ,with or without  Q waves in leads ll, lll , aVF , are 
considered to have inferior wall infarction. 
Anterior wall infarction :  In Patients with ST elevation ,with or without  Q 
waves in any  two  contiguous  leads from V1 – V6 and L1 and aVL are 
considered to have anterior wall infarction. 
FOLLOW UP  
       Patients were followed up until they were  discharged from the hospital. 
ECHO evaluation was done whenever possible. 
Statistical method  : Univariate analysis was done by the chi-square test and 
multivariate analysis by logistic regression was done using SPSS windows 
computer software. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observations and Results  
OBSERVATIONS AND RESULTS 
A total of 83 patients were studied. Their age ranged from 34 – 76 
years (mean 55.03 yrs).68 of them were males (82%) and 15 females (18%) 
20 of them were hypertensives  (24%) .44 people were smokers (53%) and 
29 (59%) consumed alcohol. 23 patients experienced preinfarction angina 
(28%) . 50 patients had anterior wall infarction (60%) and 33 patients (40%)  
had inferior infarction . 
TABLE – 1 
CLINICAL DETAILS OF STUDY POPULATION 
ACCORDING TO THE OUTCOME OF THROMBOLYSIS 
       VRIABLE SUCCESS  (%)  FAILED (%) 
NUMBER  44(53%) 39(47%) 
MALES 36(53%) 32(47%) 
FEMALES 8(53%) 7(47%) 
HYPERTENSION 11(55%) 9(45%) 
DIABETES 11(55%) 9(45%) 
SMOKING 22(50%) 22(50%) 
DRINKING 20(69%) 9(31%) 
PREINFARCTION ANGINA 9(39%) 14(61%) 
TIMEWINDOW   
0-4 HRS 21(64%) 12(31%) 
4 -8 HRS 20(39%) 20(50%) 
8-12 HRS 3(30%) 7(70%) 
AGE GROUP   
<60 YRS 30(62%) 18(38%) 
>60 YRS 14(40%) 21(60%) 
ANTERIORWALL INFARCT 20(40%) 30(60%) 
INFERIOR WALL INFARCT 24(72%) 9(28%) 
TABLE-2 
     UNIVARIATE ANALYSIS FOR INFLUENCING FACTORS 
S. 
No 
Variables 
Odds 
ratio 
(X
2
) 
Chi square 
P Value Comments 
1 Age <60 years 2.50 4.11 0.04 Significant 
2 Gender( female sex)  0.00 0.98  
3 Preinfarction angina 0.46 2.43 0.98  
4 Diabetes 1.11 0.04 0.83  
5 Hypertension   0.04 0.04  
6 Smoking   0.34 0.56  
7 Drinking  2.78 4.55 0.03 Significant 
8 Infarct location (anterior) 0.25 8.55 0.004 Significant 
 
TABLE – 3 
LOGISTIC REGRESSION ANALYSIS 
 
 
  
S. No Variables Odds(Ratio) P Value  
1 Age <60 yrs 0.4036 0.09  
2 Dinking  3.16 0.06  
3 Location of MI  3.18 0.02 Significant 
4 Smoking  0.34 0.08  
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Discussion 
  
DISCUSSION 
The major finding of this study is that the location of the infarct  
significantly affects the outcome of thrombolysis. Those with inferior wall 
myocardial infarction have a 3.18 times chance of undergoing successful 
thrombolysis compared to anterior wall myocardial infarction(p=0.02) .This 
is after adjustment for confounding variables like time window ,age 
,smoking status, gender, diabetes and hypertension. 
Similar observation was made by the Gibson ,Murphy and Braunwald 
et al(TIMIsubgroup). They found that TIMI grade lll flow rates were lower 
for left coronary and circumflex artery copared to right coronary artery after 
thrombolytic therapy.80 
The reason for this differential response will be evident when we look 
into the physiology of coronary circulation in the left coronary arteries. 
 Blood flow in the right coronary artery is relatively independend of 
the phases of cardiac cycle being present in both systole and diastole. Where 
as flow in the left coronary artery is almost absent during systole and may 
even be reversed in conditions of heightened microvascular tone and left 
ventricular hypertrophy.81  
 
The relatively thicker wall, the increased wall thickening  during 
systolic contraction and higher intracavitory pressure of left ventricle may all 
produce higher intramyocardial pressure than that is observed in the thinner 
walled right ventricle which is also subjected to lower filling pressures. 
More over the extent of necrosis in the anterior wall is more resulting 
in increased myocardial edeme copared to inferior infarctions. This may 
further decrease the reperfusion rates in anterior infarctions.  Yet another 
mechanism may be, better drug delivery to the right coronary and prolonged 
contact of streptokinase with the thrombus ,resulting in more efficient 
fibrinolysis. 
ALCOHOL AND THROMBOLYSIS 
 Alcohol consumption has influenced the outcome of the thrombolytic 
therapy in a favourable way. Univariate analysis revealed a success rate of 
69% in the drinkers verses 44% in non drinkers.(p=0.03,odds ratio=2.78). 
This advantage of drinkers persisted after logistic regression analysis to 
remove the confounding factors, even though statistically not significant . 
(odds ratio=3.16.p=0.06). 
Alcohol is known to reduce coronary artery disease related mortality. 
In a meta analysis of all experimental studies that assessed the effects of 
moderate alcohol consumption on the concentrations of LDL cholesterol , 
apolipoprotein A1,fibrinogen, triglycerides and other biological markers 
,Rimm,William,Fosher et al.  82 concluded that 30mg of alcohol /day would 
caus an estimated reduction of 24.7% in risk of coronary artery heart disease. 
This better success rate observed in patients who consume alcohol 
may be easily explained by the effect of alcohol on hemostatic factors. In a 
study conducted on 631 apparently healthy male physicians the plasma 
levels of tPA antigen were 10.9, 9.7, 9.1, and 8.1ng/ml respectively in those 
who consumed alcohol daily, weekly, once a month and never. 83 
Studies have shown alcohol has an effect on platelets also. Alcohol 
reduces platelet aggregation in response to most agonists like thrombin, 
ADP, epinephrine and collagen.      
   By contrast in binge drinkers or in alcoholics after alcohol 
withdrawal response to aggregation especially that induced by thrombin is 
markedly increased. This rebound phenomenon may be explained ischemic 
strokes or sudden death known to occur after episodes of drunkenness. 
Ehanol intake is also known to decrease blood fibrinogen level. Thus 
those who consume alcohol on a moderate basis are having better 
endogenous fibrinolytic response. 
 AGE OF THE PATIENT  
Patients older than 60 years are found to have a lesser success rate in 
univariate analysis.(X2= 4.11,odds ratio = 2.5 ,P = 0.04). after adjustment 
for other parameters in the logistic regression ,a statistically significant 
reduction in success rate is observed.  
This shows that with respect to fibrinolysis elderly people do not 
behave diffently from younger. This is reflected in reduction in mortality rate 
among elderly after thrombolysis. In patients aged more than 75 yrs who 
were treated with streptokinase in GISSI-2 trial, there was a reduction of 4.2 
fewer deaths per 100 patients than in controls.In ISIS- 2 there was 3.3 fewer 
deaths per 100 patients in those over 70 yrs of age who were treated. 84,88,89 
GENDER 
No statistically significant difference was noticed based on the gender. 
Woodfield, Luderberg, topol et al .performed an angiographic study to find 
out the patency rate at 90 minutes in men verses women. At 90 minutes 
TIMI-3 flow rate was 39% in woman and 38% in men,which was not 
satistically significant. But 30 day mortality was 13.1 im women versus 4.8  
in men(p=0.001).90,91,92,93 Thus even though  females have a poor outcome 
after myocardial infarction, they donot behave differently to the thrombolytic 
therapy. 
HYPERTENSION  
Hypertensives did not show any difference in the success rate in thus 
study. High blood pressure often confers silent cardiovascular risk, and its 
prevalence is steadily increasing. Most epidemiological studies now 
recognize the joint contributions of systolic and diastolic blood pressure to 
the development of cardiovascular risk, an issue that has markedly changed 
strategies for risk detection. The results of the TROPHY trial support  
treating prehypertensives and the feasibility of treatment.  However, outcome 
trials demonstrating that the initiation of pharmacological therapy in 
prehypertensives indicated in the presence of other major comorbidities such 
as diabetes, renal dysfunction, or known vascular disease. Patients is 
superior to initiating treatment at the time of hypertension diagnosis are 
lacking. By contrast, pharmacological therapy is mandated for those with 
stage 1 hypertension (systolic blood pressure 140 to 159 mmHg or diastolic 
blood pressure 90 to 99 mmHg) or stage 2 hypertension (systolic blood 
pressure higher than 160 mmHg or diastolic blood pressure higher than 100 
mmHg).100 
DIABETES MELLITUS  
In this study success rate of thrombolysis in diabetics is not found to 
be different from non diabetic population. 
Gray, Yudkin et al. found a reduction in reperfusion rates in 
thrombolysed diabetic population. Diabetes is a prothrombotic state as 
reflected by the increased blood levels of fibrinogen, factor Vll and  von 
willebrand factor. These changes are even more increased if diabetic people 
are happened to be smokers.86,94 
Platelet function is also impaired in diabetics, They aggregate more 
readily to stimuli like ADP and collagen.Glycolisation of membrane proteins 
due to chronic exposure to high blood sugar levels change in the fluidity of 
platelet membrane brought out by high concentration of cholesterol and 
triglycerides are the proposed mechanisms for these abnormalities. On the 
other hand patients with type ll diabetes have profound suppression of 
fibrinolysis. Plasminogen activator inhibitor –l levels are high in type ll 
diabetic people which is responsible for this effect. Nevertheless 
thrombolytic therapy should be administered to diabetics with acute 
myocardial infarction, because for 100 diabetic patients treated with 
thrombolytic therapy  four lives are saved. 
PREINFARCTION ANGINA 
Andreoti Vincenzo et al had demonstrated by angiographic method 
that those Acute myocardial patients who experienced preinfarction angina 
with in seven days preceeding the acute event had a more rapid 
thrombolysis. Patency rates were higher at 35 minutes but at 90 minutes both 
were same.101 
In this study success rate was same at 90 minutes in both groups. This 
is because ECG monitoring was not continuous in this study. Continuous ST 
segment monitoring may be needed to demonstrate the early achievement of 
patency in preinfarction angina patients.95,99 
SMOKING  
Outcome of thrombolysis is not affected by the smoking. In this study 
there is stastically insignificant trent towards a bad outcome.  
Gines Topol et al reported similar patency rates in smokers and non 
smokers at 90 minutes (73% verses 74%). Smokers tended to have reduced 
inhospital mortality compared to nonsmokers. but this was due to the 
favorable baseline clinical and angiographic variables in smokers. Smokers 
tended to be younger and thrombosis of less critical atherosclerotic plaque 
was the culprit lesion inthem. Smoking increases blood hematocrit 
,fibrinogen levels and platelet levels contributing to the hypercoagulable 
state promoting coronary thrombosis. Smokers are also found to have lesser 
fibrinlytic activity than nonsmokers.95,96,97,98 
PAIN TO STREPTOKINASE INTRAVAL(TIME WINDOW) 
This is the most powerful predictor of success rate. In this study also it 
is evident. Success rate was 64% in those patients thrombolysed within 4 
hours from the onset of symptoms. The success rate decreased to 55% when 
they were thrombolysed after 4 hours but within 8 hours of onset of chest 
pain. Success rate came down to 33% when streptokinase was administered 
after 8 hours but within 12 hours.85,87 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
  
CONCLUSION 
1. In this study the overall success rate of Thrombolysis was 53 %. 
2. The outcome was worse in those who aged more than 60 years. But it 
was not statistically significant. 
3. Gender was not found to influence the success rate of thrombolysis. 
4. Pre infarction angina had no effect on the success rate of thrombolysis. 
5. Better success rate has been seen in those consuming alcohol which 
was not statistically  significant. 
6. Smokers had a lesser success rate than non smokers but it did not 
reach any statistical significance. 
7. Hypertensives did not show any difference with non hypertensives in 
the success rate. 
8. Diabetics did not differ from non diabetics with respect to the success 
rate of thrombolysis. 
9. Inferior wall myocardial infarction had a better success rate than 
anterior wall myocardial infarctions and was statistically significant. 
10. Those who are having short window period had a better success rate 
after thrombolysis. Shorter the window period higher the success rate. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bibliography 
  
BIBLIOGRAPHY 
1. The American Heart Association. 2004 Heart and Stroke Statistical 
Update. Dallas, TX: American Heart Association, 2004. 
2. Hurst's The Heart  12th editionChapter 56 ;1345  
3. Braunwald  8th edition Chapter 50; 1237 
4. Homage to James B. Herrick:AContemporary Look at Myocardial 
Infarction and at Sickle-Cell Heart Disease The 32nd Annual Herrick 
Lecture of the Council on Clinical Cardiologyof the American Heart 
Association Thomas N. James, MD  ; Circulation. 2000;101:1874-
1887 
5. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden 
MS, Lang HT: Prevalence of total coronary occlusionduring the early 
hours of transmural myocardiainfarction. N Engi J Med 303: 897, 
1980 
6. Moon JC, De Arenaza DP, Elkington AG, et al: The pathologic basis 
of Q-wave and non-Q-wave myocardial infarction: A cardiovascular 
magnetic resonance study.  J Am Coll Cardiol  2004; 44:554. 
7. Wasserman EJ, Shipley NM: Atherothrombosis in acute coronary 
syndromes: Mechanisms, markers, and mediators of vulnerability.  Mt 
Sinai J Med  2006; 73:431 
8. Rosenberg RD, Aird WC: Vascular-bed–specific hemostasis and 
hypercoagulable states.  N Engl J Med  1999; 340:1555 
9. Ertl G, Frantz S: Healing after myocardial infarction.  Cardiovasc 
Res  2005; 66:22. 
10. Kher N, Marsh JD: Pathobiology of atherosclerosis—a brief 
review.  Semin Thromb Hemost  2004; 30:665. 
11. Boersma E, Mercado N, Poldermans D, et al: Acute myocardial 
infarction.  Lancet  2003; 361:847 
12. Gurm HS, Topol EJ: The ECG in acute coronary syndromes: New 
tricks from an old dog.  Heart  2005; 91:851. 
13. Bayes-de-Luna A, Wagner G, Birnbaum Y, et al: A new terminology 
for the left ventricular walls and location of myocardial infarcts that 
present Q wave based on the standard of cardiac magnetic resonance 
imaging.  Circulation  2006; 114:1755. 
14. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA Guidelines 
for the Management of Patients with ST-Elevation Myocardial 
Infarction: A report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines (Committee to 
Revise the 1999 Guidelines for the Management of Patients with 
Acute Myocardial Infarction). American College of Cardiology Web 
Site, 2006. 
15. Anderson JL, Adams CD, Antman EM, et al: ACC/AHA 2007 
guidelines for the management of patients with unstable angina/non-
ST-elevation myocardial infarction: A report of the American College 
of Cardiology/American Heart Association Task Force on Practice 
Guidelines (Writing Committee to Revise the 2002 Guidelines for the 
Management of Patients With Unstable Angina/Non-ST-Elevation 
Myocardial Infarction).  J Am Coll Cardiol  2007; 
 
16.  Different Quantitative Apoptotic Traits in CoronaryAtherosclerotic 
Plaques From Patients With Stable Angina Pectoris and Acute 
Coronary Syndromes Marco L. Rossi, MD; Nicola Marziliano, PhD; 
Piera Angelica Merlini, MD; Ezio Bramucci, MD; Umberto Canosi, 
MD; Guido Belli, MD; Dennis Zavalloni Parenti, MD; Pier 
Mannuccio Mannucci, MD; Diego Ardissino, MD Circulation 
2004;110;1767-1773 
17.  Ertl G, Frantz S: Healing after myocardial infarction.  Cardiovasc 
Res  2005; 66:22 
18.  High Levels of Platelet Inhibition With Abciximab Despite 
Heightened Platelet Activation and Aggregation During Thrombolysis 
for Acute Myocardial Infarction Results From TIMI (Thrombolysis In 
Myocardial Infarction) 14 Stephanie A. Coulter, MD; Christopher P. 
Cannon, MD; Kenneth A. Ault,  Elliott M. Antman, MD; Frans Van 
de Werf, MD, PhD; A.A. Jennifer Adgey, MD;C. Michael Gibson, 
MS, MD; Robert P. Giugliano, MD, SM; Mary A. Mascelli, PhD; Joel 
Scherer, MD; Elliot S. Barnathan, MD; Eugene Braunwald, MD; Neal 
S. Kleiman, MD; for the TIMI 14 Platelet Substudy Investigators 
;Circulation 2000;101;2690-2695 
19.  Fibrin D-Dimer and ß - Thromboglobulin as Markers of Thrombogenesis 
and  Platelet Activation in Atrial  Fibrillation Effects of Introducing 
Ultra–Low-Dose Warfarin and AspirinGregory Y.H. Lip, MD, 
MRCP; Peck Lin Lip, MBChB, FRCS(Edin); John Zarifis, MD;Robert    
D.S. Watson, MD, FRCP; David Bareford, MD; Gordon D.O. Lowe, 
MD, FRCP;D. Gareth Beevers, MD, FRCP .Circulation. 1996;94:425-43 
 
20. Prevention Conference VI Diabetes and Cardiovascular Disease 
Writing Group V: Management of Cardiovascular-Renal 
Complications Robert O. Bonow, MD, Chair; William E. Mitch, MD; 
Richard W. Nesto, MD; Patrick T. O’Gara, MD; Richard C. Becker, 
MD; Luther T. Clark, MD; Sharon Hunt, MD; Ishwarlal Jialal, MD; 
Stephen E. Lipshultz, MD; Evan Loh, MD Circulation. 2002;105:e132 
21. Considerable Time From the Onset of Plaque Rupture and/or Thrombi 
Until the Onset of Acute Myocardial Infarction in Humans Coronary 
Angiographic Findings Within 1 Week Before the Onset of Infarction 
Shinsuke Ojio, MD; Hisato Takatsu, MD; Tsutomu Tanaka, 
MD; Katsumi Ueno, MD; Koichi Yokoya, MD;Tetsuo Matsubara, 
MD; Takahiko Suzuki, MD; Sachiro Watanabe, MD; Norihiko Morita, 
MD; Circulation. 2000;102:2063 
22. Proteolysis of Tissue Factor Pathway Inhibitor-1 by Thrombolysis in 
Acute Myocardial Infarction Ott, Ilka MD; Malcouvier, Valerie; 
Schömig, Albert MD; Neumann, Franz-Josef MD Circulation: Journal 
of the American Heart Association Issue: Volume 105(3), 22 January 
2002, pp 279-281 
23. Coronary Artery Disease/Myocardial Infarction: Plasmin-Mediated 
Activation of Contact System in Response to Pharmacological 
Thrombolysis Ewald, Gregory A.; Eisenberg, Paul R. Circulation 
Issue: Volume 91(1), 1 January 1995, pp 28-36 
24. Libby: Braunwald's Heart Disease: A Textbook of Cardiovascular 
Medicine, 8th ed;1220-1221 
25. Lombardi F, Sandrone G, Spinnler MT, et al: Heart rate variability in 
the early hours of an acute myocardial infarction.  Am J 
Cardiol  1996; 77:1037. 
26. Killip III T, Kimball JT: Treatment of myocardial infarction in a 
coronary care unit. A two year experience with 250 patients.  Am J 
Cardiol  1967; 20:457 
27. Antman EM, Morrow DA, McCabe CH, et al: Enoxaparin versus 
unfractionated heparin with fibrinolysis for ST-elevation myocardial 
infarction.  N Engl J Med  2006; 354:1477. 
28. Sugiura T, Nakamura S, Kudo Y, et al: Clinical factors associated with 
persistent pericardial effusion after successful primary coronary 
angioplasty.  Chest  2005; 128:798. 
29. Joint European Society of Cardiology/American College of 
Cardiology Committee.. Myocardial infarction redefined. A consensus 
document of the Joint European Society of Cardiology/American 
College of Cardiology Committee for the redefinition of myocardial 
infarction. Eur Heart J 2000; 21: 1502-1513 
30. Ferguson JL, Beckett GJ, Stoddart M, Walker SW, Fox KA. 
Myocardial infarction redefined: the new ACC/ESC definition, based 
on cardiac troponin, increases the apparent incidence of infarction. 
Heart 2002 Oct;88(4):343-7 
31. Lopez-Sendon J, Lopez De Sa E. New diagnostic criteria for 
myocardial infarction: order in chaos. Rev Esp Cardiol 2001 
Jun;54(6):669-74 
32. Bogaty P, Boyer L, Rousseau L, Arsenault M: Is anteroseptal 
myocardial infarction an appropriate term?.  Am J Med  2002; 113:37. 
 
 
33. Bacharova L, Selvester RH, Engblom H, Wagner GS: Where is the 
central terminal located? In search of understanding the use of the 
Wilson central terminal for production of 9 of the 12 
electrocardiogram leads.  J Electrocardiol  2005; 38:119. 
34. Zimetbaum PJ, Josephson ME: Use of the electrocardiogram in acute 
myocardial infarction.  N Engl J Med  2003; 348:933 
35. Yamaji H, Iwasaki K, Kusachi S, et al: Prediction of acute left main 
coronary artery obstruction by 12-lead electrocardiography. ST 
segment elevation in lead aVR with less ST segment elevation in lead 
V1.  J Am Coll Cardiol  2001; 38:1348. 
36. Nikus KC, Sclarovsky S: ST elevation in lead aVR as a sign of left 
main disease—perpetuating an error?.  Am J Cardiol  2004; 94:542. 
Kurum T, Birsin A, Ozbay G, et al: Differentiating the infarct-related 
artery on initial electrocardiogram in single or multi-vessel disease in 
acute inferior myocardial infarction and evaluating involvement of 
vessels using correspondence analysis.  Angiology  2005; 56:385.  
37.  Fiol M, Carrillo A, Cygankiewicz I, et al: New criteria based on ST 
changes in 12-lead surface ECG to detect proximal versus distal right 
coronary artery occlusion in a case of acute inferoposterior myocardial 
infarction.  Ann Noninvasive Electrocardiol  2004; 9:383 
38. Streptokinase (Streptase) [package insert]. Ottawa, Ontario: CSL 
Behring Canada, Inc; 2007 
39. Urokinase (Abbokinase, Kinlytic) [package insert]. Tucson, 
Arizona: ImaRx Therapeutics, Inc; 2007. 
40. Alteplase (Activase) [package insert]. South San Francisco, 
CA: Genentech, Inc; 2005 
41. Cathflo Activase (Alteplase) [package insert]. South San Francisco, 
CA: Genentech, Inc; 2001. 
42. Tenecteplase [package insert]. South San Francisco, CA: Genentech, 
Inc; 2000. 
43. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase 
compared with front-loaded alteplase in acute myocardial infarction: 
the ASSENT-2 double-blind randomised trial. Lancet. August 
1999;354(9180):716-22. 
44. Sinnaeve P, Alexander J, Belmans A, et al. One-year follow-up of the 
ASSENT-2 trial: a double-blind, randomized comparison of single-
bolus tenecteplase and front-loaded alteplase in 16,949 patients with 
ST-elevation acute myocardial infarction. Am Heart J. July 
2003;146(1):27-32. 
45. Cannon 3rd. RO: Mechanisms, management and future directions for 
reperfusion injury after acute myocardial infarction.  Nat Clin Pract 
Cardiovasc Med  2005; 2:88-94 
46. Goldstein JA, Lee DT, Pica MC, Dixon SR, O'Neill WW: Patterns of 
coronary compromise leading to bradyarrhythmias and hypotension in 
inferior myocardial infarction.  Coron Artery Dis  2005; 16:265-274 
47. K.K.Sethi,Ischemic Heart Disease API Text Book Of Medicine 8th 
edition volume 1, 508 -509 
48. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines 
for the management of patients with ST-elevation myocardial 
infarction: A report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines (Committee to 
Revise the 1999 Guidelines for the Management of Patients with 
Acute Myocardial Infarction)  
49. Chockalingam A, Gnanavelu G, Subramaniam T, Dorairajan 
S, Chockalingam V: Right ventricular myocardial infarction: 
presentation and acute outcomes.  Angiology  2005; 56:371-376 
50. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie 
JX, Liu LS: Early intravenous then oral metoprolol in 45,852 patients 
with acute myocardial infarction: randomised placebo-controlled 
trial.  Lancet  2005; 366:1622-1632. 
51. Sabatine MS: Something old, something new: beta blockers and 
clopidogrel in acute myocardial infarction.  Lancet  2005; 366:1587-
1589 
52. Gibson CM: Time is myocardium and time is outcomes. 
Circulation  2001 ; 104:2632-2634 
53. Schomig A, Ndrepepa G, Mehilli J, Schwaiger M, Schuhlen 
H, Nekolla S, Pache J, Martinoff S, Bollwein H, Kastrati A: Therapy-
dependent influence of time-to-treatment interval on myocardial 
salvage in patients with acute myocardial infarction treated with 
coronary artery stenting or thrombolysis. Circulation  2003; 108:1084-
1088. 
54. The Global Use of Strategies to Open Occluded Coronary Arteries-
GUSTO III-Investigators. A comparison of reteplase with alteplase for 
acute myocardial infarction.  N Engl J Med  1997; 337:1118-1123 
55. Ware JH, Antman EM: Equivalence trials.  N Engl J 
Med  1997; 337:1159-1161. 
56. White HD: Thrombolytic therapy and equivalence trials.  J Am Coll 
Cardiol  1998; 31:494-496. 
57. Assessment of the Safety and Efficacy of a New Thrombolytic 
Investigators : Single-bolus tenecteplase compared with front-loaded 
alteplase in acute myocardial infarction: the ASSENT-2 double-blind 
randomised trial.  Lancet  1999; 354:716-722. 
58. Armstrong PW, Burton J, Pakola S, Molhoek PG, Betriu A, Tendera 
M, Bode C, Adgey AA, Bar F, Vahanian A, Van de Werf 
F: Collaborative Angiographic Patency Trial Of Recombinant 
Staphylokinase (CAPTORS II).  Am Heart J  2003; 146:484-488. 
59. Ndrepepa G, Kastrati A, Schwaiger M, Mehilli J, Markwardt C, Dibra 
A, Dirschinger J, Schomig A: Relationship between residual blood 
flow in the infarct-related artery and scintigraphic infarct size, 
myocardial salvage, and functional recovery in patients with acute 
myocardial infarction.  J Nucl Med  2005; 46:1782-1788. 
60. Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin 
ML, Williams DO, Forman SA: Thrombolytic therapy vs primary 
percutaneous coronary intervention for myocardial infarction in 
patients presenting to hospitals without on-site cardiac surgery: a 
randomized controlled trial.  JAMA  2002; 287:1943-1951. 
61. Goldberger AL: Clinical Electrocardiography: A Simplified 
Approach,  7th ed.. St. Louis, Mosby/Elsevier, 2006 
62. Surawicz B, Knilans T: Chou's Electrocardiography in Clinical 
Practice: Adult and Pediatric,  Philadelphia, WB Saunders, 2001. 
 
63. Lang RM, Bierig M, Devereux RB, et al: Chamber Quantification 
Writing Group; American Society of Echocardiography's Guidelines 
and Standards Committee; European Association of Echocardiography 
:  Recommendations for chamber quantification: A report from the 
American Society of Echocardiography's Guidelines and Standards 
Committee and the Chamber Quantification Writing Group, developed 
in conjunction with the European Association of Echocardiography, a 
branch of the European Society of Cardiology.  J Am Soc 
Echocardiogr  2005; 18:1440 
64. Holmes DR, Laskey WK, Wondrow MA, Cusma JT: Flat-panel 
detectors in the cardiac catheterization laboratory: Revolution or 
evolution—what are the issues?.  Catheter Cardiovasc 
Interv  2004; 63:324-330. 
65. Fiol M, Carrillo A, Cygankiewicz I, et al: New criteria based on ST 
changes in 12-lead surface ECG to detect proximal versus distal right 
coronary artery occlusion in a case of acute inferoposterior myocardial 
infarction.  Ann Noninvasive Electrocardiol  2004; 9:383. 
66. Cannon 3rd. RO: Mechanisms, management and future directions for 
reperfusion injury after acute myocardial infarction.  Nat Clin Pract 
Cardiovasc Med  2005; 2:88-94. 
67. Vargas SO, Sampson BA, Schoen FJ: Pathologic detection of early 
myocardial infarction: a critical review of the evolution and usefulness 
of modern techniques.  Mod Pathol  1999; 12:635-645. 
68. Goldstein JA, Lee DT, Pica MC, Dixon SR, O'Neill WW: Patterns of 
coronary compromise leading to bradyarrhythmias and hypotension in 
inferior myocardial infarction.  Coron Artery Dis  2005; 16:265-274. 
69. Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon 
CP, Giugliano RP, Antman EM, Braunwald E: Early and long-term 
clinical outcomes associated with reinfarction following fibrinolytic 
administration in the Thrombolysis in Myocardial Infarction trials.  J 
Am Coll Cardiol  2003; 42:7-16. 
70. Grines CL, Browne KF, Marco J, et al: A comparison of immediate 
angioplasty with thrombolytic therapy for acute myocardial infarction. 
The Primary Angioplasty in Myocardial Infarction Study Group.  N 
Engl J Med  1993; 328:673. 
71. Grines C, Patel A, Zijlstra F, et al: Primary coronary angioplasty 
compared with intravenous thrombolytic therapy for acute myocardial 
infarction: Six-month follow-up and analysis of individual patient data 
from randomized trials.  Am Heart J  2003; 145:47. 
72. Sugiura T, Nagahama Y, Nakamura S, Kudo Y, Yamasaki F, Iwasaka 
T: Left ventricular free wall rupture after reperfusion therapy for acute 
myocardial infarction.  Am J Cardiol  2003; 92:282-284. 
73. Altun A, Kirdar C, Ozbay G: Effect of aminophylline in patients with 
atropine-resistant late advanced atrioventricular block during acute 
inferior myocardial infarction.  Clin Cardiol  1998; 21:759-762. 
74. Petrina M, Goodman SG, Eagle KA: The 12-lead electrocardiogram as 
a predictive tool of mortality after acute myocardial infarction: current 
status in an era of revascularization and reperfusion.  Am Heart 
J  2006; 152:11-18. 
75. Kober L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz 
R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad 
F, Ertl G, Solomon SD, Zelenkofske S, Rouleau JL, Leimberger 
JD, Califf RM: Previously known and newly diagnosed atrial 
fibrillation: A major risk indicator after a myocardial infarction 
complicated by heart failure or left ventricular dysfunction.  Eur J 
Heart Fail  2006; 
76. De Luca G, Ernst N, van't Hof AW, Ottervanger JP, Hoorntje 
JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata 
H: Predictors and clinical implications of early reinfarction after 
primary angioplasty for ST-segment elevation myocardial 
infarction.  Am Heart J  2006; 151:1256-1259. 
77. Sugiura T, Nagahama Y, Nakamura S, Kudo Y, Yamasaki F, Iwasaka 
T: Left ventricular free wall rupture after reperfusion therapy for acute 
myocardial infarction.  Am J Cardiol  2003; 92:282-284. 
78. Lesser JR, Johnson K, Lindberg JL, Reed J, Tadavarthy SM, Virmani 
R, Schwartz RS: Images in cardiovascular medicine. Myocardial 
rupture, microvascular obstruction, and infarct expansion: elucidation 
by cardiac magnetic resonance.  Circulation  2003; 108:116-117. 
79. Birnbaum Y, Chamoun AJ, Anzuini A, Lick SD, Ahmad M, Uretsky 
BF: Ventricular free wall rupture following acute myocardial 
infarction.  Coron Artery Dis  2003; 14:463-470 
80. C,Michael Gibson;Saina Murphy:IanB.A. MEnown;E,Bunwald et 
al.for TIMI study group. Determinants of coronary blood flow after 
thrombolytic therapy ,Journal of American college of cardiology 
1999;34:1403-12 
81. Lowensohan HS:Khouri EM:Grey DE,et al.Phasic right coronary 
artery blood flow in conscious dogs with normal and elevated right 
ventricular pressure. Circulation Research 2001:39:760-6 
82. Eric B Rimm,Paige Williams: Kerry Fosher et al. Moderate alcohol 
intake and lower risk of coronary artery heart disease : metaanalysis of 
effect on lipids and haemostatic factors .British medical Journal 
2004:1523-1528  
83. Ridker Pm : Vaughan DE ,Stamper MJ: Glym RJ: Henneken CH . 
Association of moderate alcohol consumption and plasma 
concentration of endogenous tissue type plasminogen activator JAMA 
2004.28:272(12):929-33 
84. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe 
CH, Cannon CP, Van de Werf F, Braunwald E: Relationship between 
TIMI frame count and clinical outcomes after thrombolytic 
administration. Thrombolysis In Myocardial Infarction (TIMI) Study 
Group.  Circulation  1999; 99:1945-1950.  
85. 63. Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R, Van 
de Werf Gibson CM, Murphy SA, Kirtane AJ, Giugliano RP, Cannon 
CP, Antman EM, Braunwald E: Association of duration of symptoms 
at presentation with angiographic and clinical outcomes after 
fibrinolytic therapy in patients with ST-segment elevation myocardial 
infarction.  J Am Coll Cardiol  2004; 44:980-987. 
86. Angeja BG, de Lemos J, Murphy SA, Marble SJ, Antman 
EM, Cannon CP, Braunwald E, Gibson CM: Impact of diabetes 
mellitus on epicardial and microvascular flow after fibrinolytic 
therapy.  Am Heart J  2002; 144:649-656. 
87. Boersma E, Maas AC, Deckers JW, Simoons ML: Early thrombolytic 
treatment in acute myocardial infarction: reappraisal of the golden 
hour.  Lancet  1996; 348:771-775. 
88. White HD: Thrombolytic therapy in the elderly. Lancet  2000 
;  356:2028-2030. 
89. Stenestrand U, Wallentin L: Fibrinolytic therapy in patients 75 years 
and older with ST-segment-elevation myocardial infarction: one-year 
follow-up of a large prospective cohort.  Arch Intern 
Med  2003; 163:965-971. 
90. Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman 
A, Santopinto J, Corsini G, Terrosu P, Joulain F: The role of gender 
and other factors as predictors of not receiving reperfusion therapy and 
of outcome in ST-segment elevation myocardial infarction.  J Thromb 
Thrombolysis  2005; 19:155-161. 
91. Giugliano RP, Antman EM: Caeteris paribus—all things being 
equal.  Eur Heart J  2001; 22:2221-2223. 
92. Treatment of acute myocardial infarction and 30-day mortality among 
women and men ;Sandra c. Ghan MD, Shelly K July 6, 2000 : 8-15 
93. Relation of race and sex to the use of reperfusion therapy in medicare 
beneficiaries with acute myocardial infarction;NEJM  John G canto 
MD Robet Farmer MD April 13, 2000  1904-1100. 
94. Mukamal KJ, Nesto RW, Cohen MC, et al: Impact of diabetes on 
long-term survival after acute myocardial infarction: Comparability of 
risk with prior myocardial infarction.  Diabetes Care  2001; 24:1422. 
95. Yusuf S, Hawken S, Ounpuu S, et al: Effect of potentially modifiable 
risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): Case-control study.  Lancet  2004; 364:937. 
96. He J, Gu D, Wu X, et al: Major causes of death among men and 
women in China.  N Engl J Med  2005; 353:1124. 
97. Bazzano LA, He J, Muntner P, et al: Relationship between cigarette 
smoking and novel risk factors for cardiovascular disease in the 
United States.  Ann Intern Med  2003; 138:891. 
98. Barua RS, Ambrose JA, Srivastava S, et al: Reactive oxygen species 
are involved in smoking-induced dysfunction of nitric oxide 
biosynthesis and upregulation of endothelial nitric oxide synthase: An 
in vitro demonstration in human coronary artery endothelial 
cells.  Circulation  2003; 107:2342 
99. Julius S, Nesbitt SD, Egan BM, et al: Feasibility of treating 
prehypertension with an angiotensin-receptor blocker.  N Engl J 
Med  2006; 354:1685. 
100. Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler 
WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor 
MD, Gore JM, Krumholz HM, Ohman EM: Acute coronary care in the 
elderly. Part 2: ST-segment elevation myocardial infarction. A 
Statement for Healthcare Professionals from the Acute Cardiac Care 
Subcommittee, Council on Clinical Cardiology, American Heart 
Association; Endorsed by the Society of Geriatric 
Cardiology.  Circulation  2007; 115:2570-2589 
101. Felicita Andreoti : Vencenzo pasceri  : David R Hacket Attlio Maseri 
et al .Preinfarction angina as a predictor of more rapid coronary 
thrombosis in patients acute myocardial infarction, NEJM 
20001:334:7 – 12. 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
  
LIST OF ABBREVIATIONS USED IN THE PROFORMA  
AND IN THE DISSERTATION 
 
AMI : Acute Myocardial Infarction 
PAI -1 : Plasminogen Activator Inhibitor – 1 
PDGF : Platelet Derived Growth Factor 
VVW : Von Willebrand factor 
APSAC : Anisollated Plasminogen Streptokinase Activator Complex 
LBBB : Left Bundle Branch Block 
RBBB      : Right Bunle Branch Block 
RCA : Right Coronary Artery 
LCA : Left Coronary Artery 
LCX : Left Circumflex Artery  
LAD : Left Anterior Descending 
PTCA : Percutaneous Transluminal Coronary Angioplasty 
SK : Steptokinase 
rtPA         :     Recombinant tissue plasminogen Activator 
LV : Left Ventricle 
RV : Right Ventricle 
VF : Ventricular Fibrillation 
VT : Ventricular tachycardia 
CABG : Coronary Artery Bypass Graft 
ECG :  Electro cardio graph 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proforma 
  
PROFORMA 
 
NAME  :  AGE : SEX     : 
ADDRESS :  OCCUPATION  : 
HISTORY     
CHEST PAIN :  DURATION :                              LOCATION : 
ASSOCIATED  SYMPTOMS  : 
SWEATING                                       RADIATION OF  PAIN 
PALPITAION                                     BREATHLESSNESS  
PAST HISTORY OF   
SYSTEMIC HYPERTENSION (DURATION) : 
DIABETIC  MELLITUS (DURATION) : 
CORONARY ARTERY DISEASE(DURATION) : 
SMOKING   : 
ALCOHOL   CONSUMPTION  : 
GENERAL EXAMINATION  : 
 PALLOR/JAUNDICE/CYNOSIS/CLUBBING/PEDAL EDEMA PULSE : 
BLOOD PRESSURE (AT THE TIME OF ADMISSION)  : 
RESPIRATORY RATE  : 
TEMPERATURE  : 
 
SYSTEM EXAMINATION 
CARDIOVASCULAR SYTEM  
 S1 ,S2, S3 ,MURMUR , ADDED  SOUNDS  : 
RESPIRATORY SYSTEM 
 BREATH SOUNDS  , ADVENTITIOUS SOUNDS : 
 ABDOMINAL EXAMINATION 
 ORGANOMEGALY, FREE FLUID :    
NERVOUS SYSTEM 
 ANY FOCAL NEUROLOGICAL DEFICITS : 
 
 ECG: 
 AT THE TIME OF ADMISSION : 
PRESENCE OF BUNDLE BRANCH BLOCKS , ARRHYTHMIAS : 
LOCATION OF MYOCARDIAL INFARCTION : 
AFTER THROMBOLYSIS   : 
 
TREATMENT 
 TIME INTRAVAL BETWEEN THE ONSET OF PAIN AND THE INITIATION OF 
THROMBOLYTIC THERAPY: 
 
EFFECT OF THROBOLYSIS: 
CLINICALLY COMPLETE  SUBSIDENCE OF CHEST PAIN : 
 
ECG  -   MORE THAN 50% ST-RESOLUTION (SUCCESSFUL THROMBOLYSIS) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consent Form  
DEPARTMENT OF GENERAL MEDICINE , 
COIMBATORE MEDICAL COLLEGE HOSPITAL. 
 STUDY ON FACTORS INFLUENCING OUTCOME OF THROMBOLYSIS IN ACUTE 
MYOCARDIAL INFARCTION 
 
Informed consent form for prospective participants 
 
Principal Investigator : Dr Pratheesh P. P, Junior Resident. 
Research Guide : Prof. Dr Raveendran .MD,Chief, Medical Unit – IV. 
Organization : Department of Medicine, Coimbatore Medical College Hospital. 
 
This informed consent form has two parts 
PART – I  INFORMATION SHEET(to share the information about the research with you) 
PART – II CERTIFICATE OF CONSENT (for signatures if you agree to take part) 
(You will be given a copy of the full informed consent form.) 
PART – I  INFORMATION SHEET 
I , Dr Pratheesh P.P, Junior resident in Dept of Medicine invites you to join as participant in my 
research on thrombolysis in acute myocardial infarction . I am going to give you information and 
invite you to be part of this research. You do not have to decide today whether or not you will 
participate in the research. Before you decide, you can talk to anyone you feel comfortable with 
about the research.  
There may be some words that you do not understand. Please ask me to stop as we go through the 
information and I will take time to explain.  If you have questions later, you can ask them of me, 
the study doctor or the staff. 
Thrombolysis in acute myocardial infarction is a life saving procedure. By lysing the thrombus 
and successful reperfusion , further injury to the myocardium can be prevented. We are doing this 
research to predict the outcome of thrombolysis  and thereby focus our prevention and treatment 
efforts in a better way. 
In this study you will have to answer questions regarding your illness, undergo a physical 
examination , give urine and blood for tests, undergo a radiological exam of chest and an 
electrocardiogram. 
Your participation in this research is entirely voluntary. It is your choice whether to participate or 
not. Whether you choose to participate or not, all the services you receive at this clinic will 
continue and nothing will change. You may change your mind later and stop participating even if 
you agreed earlier. 
You will have to give details regarding your age, duration of disease, family history of the 
disease, any symptoms you are having at present, your past medical problems, surgeries and 
current medications. A doctor will examine you to look for any problems. Your height and weight 
will be recorded. All the data will be recorded in a proforma. Ten ml of blood will be drawn for 
doing various laboratory tests to know about the status of your disease. Any excess sample will be 
destroyed immediately after the laboratory tests are completed. Taking the blood sample will 
produce some pain and there may be slight redness at the site of puncture for a day or two. Also 
you will have to provide 3 ml or urine for tests to detect protein. You will be subjected to a 
radiological exam of the chest and an electrocardiogram(ECG) will be recorded all of which are 
painless procedures. 
On the first day you will be asked about your problems, a doctor will check you up and an ECG 
will be taken. You will also have to give the blood and urine samples. A chest x-ray will also be 
taken 
In total you will have to visit  twice or thrice for the research purpose. By participating in this 
research it is possible that you may experience some discomfort as each of your visits will take 
longer than your usual bi-weekly follow up visits and will involve needle pricks to give blood 
samples. 
If you participate in this research you will be having a thorough check up, which may reveal some 
unidentified problems in you. We will promptly start the treatment for them. Also by participating 
you are providing valuable data that will help doctors understand this disease better and ultimately 
serve the patients in a better way. 
We will not be providing any money for participating in this research, you may incur more 
expense since you will have to visit the hospital more frequently. 
It is possible that if others in the community are aware that you are participating in this research, 
they may ask you questions. We will not be sharing the identity of those participating in the 
research with anyone. The information that we collect from this research project will be kept 
confidential. Information about you that will be collected during the research will not be identified 
by your name but by a number. Only the researchers will know what your number is and they will 
lock that information up with a lock and key. It will not be shared with or given to anyone except 
my research guide. 
The knowledge that we get from doing this research will be shared with you before it is made 
widely available to the public. Confidential information will not be shared. There will be small 
meetings in the community and these will be announced. After these meetings, we will publish 
the results in order that other interested people may learn from our research 
You do not have to take part in this research if you do not wish to do so. You may also stop 
participating in the research at any time you choose. It is your choice and all of your rights will 
still be respected 
If you have any questions you may ask them now or later, even after the study has started. If you 
wish to ask questions later, you may contact  
 
DR PRATHEESH P.P. PROF .DR.M. RAVEENDRAN .MD. 
Junior Resident, Chief, Medical Unit – IV, 
Dept Of Medicine, Dept Of Medicine, 
Coimbatore Medical College Hospital Coimbatore Medical College Hospital, 
Coimbatore – 18. Coimbatore- 18. 
Phone – 9894295258.     
 
This proposal has been reviewed and approved by the Ethics Committee of Coimbatore Medical 
College Hospital which is a committee whose task it is to make sure that research participants are 
protected from harm. 
PART – II CERTIFICATE OF CONSENT 
I have been invited to participate in research on diabetes. I understand that it will involve 
answering a detailed questionnaire, undergoing a thorough physical exam, giving blood and urine 
samples and two or three  follow-up visits. I have been informed that the risks are minimal and 
may include only slight pain and redness at sight of needle prick. I am aware that there may be no 
benefit to me personally and that I will not be compensated monetarily. I have been provided with 
the name of a researcher who can be easily contacted using the number and address I was given 
for that person. 
I have read the foregoing information or it has been read to me. I have had the opportunity to ask 
questions about it and any questions I have asked have been answered to my satisfaction. I 
consent voluntarily to participate as a participant in this research and understand that I have the 
right to withdraw from the research at  anytime without in anyway affecting my medical care. 
 
Name of the participant: ________________________________________________ 
 
Signature of the participant: ________________________________________________ 
 
Date:    ________________________________________________ 
     (Day/Month/Year) 
 
If illiterate 
 
A literate witness must sign (if possible , this person should be selected by the participant and 
must have no connection to the research team) 
 
I have witnessed the accurate reading of the consent form to the potential participant , translated 
to his mother tongue,  and the individual has had opportunity to ask questions. I confirm that the 
individual has given consent freely. 
 
Name of witness :       _________________________  AND        Thumb print of participant 
Signature of witness :  _________________________ 
Date  : _________________________ 
    
 
 
(Day/Month/Year) 
 
I have accurately read or witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that the 
individual has given consent freely. 
 
Name of the researcher :  ______________________________________ 
Signature of the researcher :  ______________________________________ 
Date : ______________________________________ 
    (Day/Month/Year) 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Master Chart 
  
Sl.no IP.no 
   
Age 
  Sex 
 Hyper-
tension 
Diabetes Smoking Alcohol 
 
Preinfarction 
Angina 
Location of 
MI 
Window 
period 
(hrs) 
Successful 
thrombolysis 
1 11378 48  MALE  NO  NO YES YES NO INFERIOR 3 YES 
2 11962 49 MALE YES NO YES YES YES ANTERIOR 6 NO 
3 13877 46 MALE NO NO NO NO NO ANTERIOR 4 NO 
4 13374 54 FEMALE YES NO NO NO YES ANTERIOR 7 YES 
5 15632 63 MALE NO NO YES NO NO INFERIOR 10 NO 
6 15765 58 FEMALE NO NO NO NO NO INFERIOR 7 NO 
7 17945 48  MALE NO YES YES YES NO INFERIOR 4 YES 
8 19786 52 MALE YES NO NO YES NO INFERIOR 4 YES 
9 24367 66 FEMALE NO NO NO NO YES ANTERIOR 7 YES 
10 27654 67 MALE YES YES NO NO YES ANTERIOR 4 NO 
11 29567 68 MALE NO YES YES NO NO INFERIOR 3 YES 
12 32786 43 MALE NO NO YES YES NO ANTERIOR 7 YES 
13 26987 54 MALE NO YES  NO YES YES ANTERIOR 1O NO 
14 29879 41 MALE NO NO YES YES NO INFERIOR 8 YES 
15 23678 59 FEMALE YES YES NO NO NO ANTERIOR 4 YES 
16 27652 62 MALE NO NO NO NO NO INFERIOR 7 NO 
17 29806 34 MALE NO NO YES YES NO ANTERIOR 3 YES 
18 31432 51 MALE NO NO NO NO NO ANTERIOR 4 NO 
19 34786 52 MALE NO NO YES YES NO ANTERIOR 6 YES 
20 36478 70 FEMALE NO NO NO NO NO INFERIOR 10 YES 
21 38765 68 MALE YES NO YES YES YES ANTERIOR 3 NO 
22 39765 49 MALE NO NO YES NO NO ANTERIOR 6 NO 
23 41435 56 FEMALE NO YES NO NO NO INFERIOR 7 NO 
24 42598 49 MALE YES NO YES YES YES INFERIOR 4 YES 
25 45698 62 MALE NO NO NO NO NO ANTERIOR 8 NO 
26 47896 76 MALE NO YES YES NO NO INFERIOR 5 YES 
27 48089 48 MALE NO NO YES NO NO ANTERIOR 11 NO 
28 49780 54 MALE NO NO YES YES NO ANTERIOR 8 NO 
29 50098 53 MALE NO NO YES YES NO INFERIOR 9 YES 
30 50978 66 FEMALE NO NO NO NO NO ANTERIOR 8 NO 
31 52356 56 MALE NO NO NO NO NO INFERIOR 4 YES 
32 56409 58 MALE YES YES YES NO YES ANTERIOR 4 NO 
33 56998 64 MALE NO NO YES YES NO INFERIOR 5 YES 
34 57664 50 MALE YES NO NO NO YES ANTERIOR 6 YES 
35 57699 61 MALE NO NO YES YES NO ANTERIOR 10 NO 
36 58997 47 MALE NO NO NO NO NO ANTERIOR 8 NO 
37 59076 55 FEMALE NO NO NO NO NO ANTERIOR 4 YES 
38 60885 61 MALE NO NO YES NO NO INFERIOR 6 NO 
39 60994 42 MALE YES NO NO NO YES ANTERIOR 4 NO 
40 61445 51 MALE NO NO YES YES NO INFERIOR 2 YES 
41 65890 63 MALE NO NO YES YES NO ANTERIOR 8 NO 
42 62347 45 MALE NO YES YES NO NO INFERIOR 5 YES 
43 67497 65 FEMALE NO YES NO NO NO ANTERIOR 10 NO 
44 68795 67 MALE NO NO YES NO NO ANTERIOR 7 YES 
45 68907 51 MALE YES NO YES YES YES INFERIOR 4 YES 
46 69876 65 FEMALE NO YES NO NO NO INFERIOR 6 YES 
47 69976 55 MALE NO NO YES YES NO ANTERIOR 4 NO 
48 70986 72 MALE NO NO NO NO YES ANTERIOR 4 NO 
49 71456 55 MALE NO NO YES NO NO ANTERIOR 6 YES 
50 71987 68 MALE YES YES NO NO YES INFERIOR 12 NO 
51 72997 57 MALE NO NO YES NO NO ANTERIOR 8 NO 
52 67859 58 MALE YES YES NO YES YES INFERIOR 3 YES 
53 98065 64 FEMALE NO NO NO NO YES INFERIOR 8 NO 
54 89750 53 MALE NO NO YES NO NO ANTERIOR 4 NO 
55 89765 54 FEMALE NO NO NO NO NO ANTERIOR 9 YES 
56 89706 68 MALE YES NO YES NO NO INFERIOR 5 YES 
57 76504 47 MALE NO NO YES YES NO ANTERIOR 6 YES 
58 79806 51 MALE NO NO NO NO NO ANTERIOR 8 NO 
59 78640 67 MALE YES NO NO NO YES ANTERIOR 6 YES 
60 74650 44 MALE NO NO NO NO NO INFERIOR 4 YES 
61 67548 66 MALE NO YES YES NO  YES ANTERIOR 8 NO 
62 67858 66 MALE NO NO YES YES NO ANTERIOR 8 NO 
63 87659 49 MALE NO NO YES NO NO ANTERIOR 3 YES 
64 98765 64 FEMALE YES NO NO NO YES INFERIOR 4 NO 
65 67975 62 MALE NO YES NO YES NO INFERIOR 6 YES 
66 94532 46 MALE NO NO NO NO YES ANTERIOR 5 YES 
67 99567 67 MALE NO NO YES NO NO ANTERIOR 10 NO 
68 89765 50 MALE NO NO YES NO NO ANTERIOR 8 NO 
69 87659 64 MALE NO YES YES YES NO INFERIOR 3 YES 
70 91342 57 MALE YES NO NO NO YES ANTERIOR 6 YES 
71 96045 61 MALE NO YES YES NO NO ANTERIOR 4 NO 
72 98564 60 MALE NO NO NO NO NO ANTERIOR 8 NO 
73 90675 50 MALE NO NO YES YES NO INFERIOR 4 YES 
74 95643 68 MALE YES NO NO NO YES ANTERIOR 8 NO 
75 98748 48 MALE NO NO NO NO NO INFERIOR 4 YES 
76 98750 67 MALE NO NO YES YES NO ANTERIOR 3 YES 
 
97604 56 FEMALE YES YES NO NO YES INFERIOR 8 NO 
78 98765 38 MALE NO NO NO YES NO ANTERIOR 4 YES 
79 90436 61 FEMALE YES YES NO NO YES ANTERIOR 6 YES 
80 90862 67 MALE NO NO YES YES NO ANTERIOR 4 NO 
81 97651 56 MALE NO NO YES YES NO INFERIOR 4 YES 
82 98067 66 MALE NO NO YES NO NO INFERIOR 8 YES 
83 99453 53 MALE NO YES YES NO NO ANTERIOR 4 YES 
 
